

CURRICULUM VITAE

PROFESSOR ARLENE CHAN AM
MB BS, FRACP, MMed (Palliative Care)

Place of birth	Hong Kong
Address	101 Monash Avenue Nedlands 6009 Western Australia, AUSTRALIA
Telephone:	61-8-94814522
Fax:	61-8-94814544
Email:	arlenechan@me.com



February 2019

RESEACH GRANTS & AWARDS

1. Investigator-initiated research grant Sanofi Australia: Study of Pre-operative TAC (Docetaxel, Doxorubicin, Cyclophosphamide) in conjunction with the development of a standard protocol for the management of locally advanced breast cancer 2006 (XRP6976D/6164) \$110,000.00
2. Investigator-initiated research grant Sanofi Australia: Prevalence of epiphora in women with early breast cancer receiving adjuvant docetaxel-based chemotherapy 2009 (TAX-AU-6034) \$250,000.00
3. Investigator-initiated research grant Amgen Australia: Assessment of the incidence of significant myelosuppression in early breast cancer patients receiving standard adjuvant chemotherapy in a single institution 2010 \$10,500.00
4. Investigator-initiated research grant Roche Australia: Retrospective study of the rate of HER2 neu discordance between primary breast carcinoma and locoregional or metastatic disease 2010 \$120,000.00
5. Investigator-initiated research grant Sanofi Australia: Review of the prevalence of triple negative breast cancer (TNBC) and its management in 3 large breast cancer centres in Australia 2011 \$40,000.00
6. Investigator-initiated research grant GSK Australia: Multicentre Phase II, open label trial of lapatinib and vinorelbine in women with previously treated her2/neu positive metastatic breast cancer 2009 \$1,100,000.00
7. Investigator-initiated research grant Novartis Australia: Phase II randomised, placebo-controlled study to evaluate the efficacy of topical pure emu oil for arthralgic pain related to aromatase inhibitor use in postmenopausal women with early breast cancer: 2009 JUST Joints Under Study \$40,000.00
8. Investigator-initiated research grant (GSK, SanofiAventis, MerckSerono, AstraZeneca) Survey of treatment and trial participation in oncology private practice (STOPP) 2009 \$120,000.00
9. BCRC-WA Grant for Pilot study to evaluate adverse events during adjuvant treatment with the development of an algorithm for patient management between multidisciplinary specialist team and the family physician 2012 \$14,300
10. Pfizer Australian Physicians Independent Committee Grant for Retrospective evaluation of markers of DNA repair competency in primary triple negative breast cancer: breast cancer outcome following standard adjuvant chemotherapy in tumours with or without competency of DNA repair 2012 \$48,000.00
11. BCRC-WA Grant for Randomised Phase II study to evaluate the impact of Aerobic and Resistance Exercise on fatigue in patients with Advanced breast cancer (AREA study) 2014 \$28,000
12. BCRC-WA Grant for Establishing the prognostic importance of key immune suppressor cells and molecules in the primary tumour and regional nodes of patients with Luminal B breast cancer (IMIB study) 2014 \$24,680

CLINICAL ACHIEVEMENTS

- **1998** Establishment of the High-risk genetics breast cancer assessment and surveillance clinic at Royal Perth Hospital
- **2002** Establishment of Royal Perth Hospital-based Cancer Registry
- **2003** Establishment of Breast Clinical Trials Unit based at the Mount Hospital. Has been principal investigator of 76 single and multicentre breast cancer clinical trials conducted by the Breast Clinical trials Unit, with recruitment of more than 1000 patients. Results from nine of these trials led to change in the global standard of care for patients diagnosed with breast cancer
- **2006** Nominated for Western Australia of the Year, Perth, Western Australia
- **2009** Established Breast Cancer Research Centre-WA. BCRC-WA is a charitable research group, which is incorporated as a not-for-profit organisation. The goals of BCRC-WA are to conduct research into the causes, prevention and treatment of breast cancer, enhance the multidisciplinary care to individuals with breast cancer and their carers by providing greater support and improving quality of life and to improve the provision of information about breast cancer to women and their families.
- **2011** Visiting Professor for the Chinese International Medical Tribune to Shanghai
- **2013** Finalist of Western Australia of the Year Awards, Perth, Western Australia
- **2016** Winner, Professions, Western Australia of the Year Awards, Perth, Western Australia
- **2017** Finalist, Australian of the Year Awards 2017, Perth, Western Australia
- **2017** Inducted into Western Australia Women Hall of Fame
- **2018** Member of the Order of Australia

PRINCIPAL INVESTIGATOR OF INVESTIGATOR-INITIATED RESEARCH

- Evaluating biological alterations in HER2/neu positive metastatic breast cancer during treatment with targeted therapy
- Multimodality treatment approach for locally advanced breast cancer
- Prevalence and mechanism underlying epiphora in adjuvant taxane therapy for early breast cancer
- Placebo controlled trial of topical intervention for arthralgias associated with aromatase inhibitors in early breast cancer
- Multicentre evaluation of the prevalence of and response to conventional systemic therapy for triple negative breast cancer
- Assessment of relative dose intensity of standard adjuvant chemotherapy regimens in early breast cancer
- Phase II study of third-line HER2/neu targeted combination therapy in HER2/neu positive metastatic breast cancer
- A retrospective study investigating the rate of HER2 discordance between primary breast carcinoma and locoregional or metastatic disease
- Retrospective review of the prevalence of triple negative breast cancer (TNBC) and its management in 3 large breast cancer centres in Australia
- Pilot study to evaluate adverse events during adjuvant treatment with the development of an algorithm for patient management between multidisciplinary specialist team and the family physician
- Retrospective evaluation of markers of DNA repair competency in primary triple negative breast cancer: breast cancer outcome following standard adjuvant chemotherapy in tumours with or without competency of DNA repair
- Incidence of Metastatic Central Nervous System disease in Breast Cancer: Impact of Tumour Sub-type
- Randomised Phase II study to evaluate the impact of Aerobic and Resistance Exercise on fatigue in patients with Advanced breast cancer (AREA study, BCRC110)
- Primary breast cancer surgery in metastatic breast cancer patients: Impact of breast cancer subtype on outcome (BCRC112)
- Establishing the prognostic importance of key immune suppressor cells and molecules in the primary tumour and regional nodes of patients with Luminal B breast cancer (IMIB study, BCRC111)
- Incidence of chemotherapy-induced alopecia in breast cancer patients: randomised trial of two temperature levels (CIA study, BCRC113)
- Early breast cancer Socioeconomic and Psychological Impact Study (ESPI, BCRC114): Identifying prevalence and nature of physical and psychosocial symptoms in breast cancer survivors seen at a tertiary referral breast cancer centre
- Pilot Study of Hippocampal Avoidance Technique for Whole Brain Radiotherapy in Stage IV Breast Cancer with Brain Metastases (HAT study BCRC115 – Co-Principal Investigator)
- Breast cancer offspring study (BCOS BCRC116)
- Males breast cancer: Tumour characteristics & treatment compared with females in Australia – a study of 99,768 patients over a 10yr period (BIMA BCRC117)

- Chemotherapy and endocrine delivery in early breast cancer in Australia (CEBAT BCRC118)
- Impact of Vitamin D Deficient as a Prognosis Factor in Early Breast Ca Outcome (BCRC121)
- Review Of Australian Prescribing Practices Of Eribulin (Rapper Study BCRC122)

POSTGRADUATE APPOINTMENTS

2011 TO PRESENT

**PROFESSOR (ADJUNCT), SCHOOL OF MEDICINE, CURTIN UNIVERSITY,
PERTH WA**

2009 TO PRESENT

VICE-CHAIR BREAST CANCER RESEARCH CENTRE – WA

2016 TO PRESENT

**DIRECTOR BREAST CLINICAL TRIALS UNIT, HOLLYWOOD PRIVATE
HOSPITAL**

**BREAST CANCER-SPECIFIC MEDICAL ONCOLOGIST, HOLLYWOOD
PRIVATE HOSPITAL**

- * Teaching responsibilities Resident medical officer, FRACP candidates, Advanced trainees in Medical Oncology, Oncology Registered nurses

1999 TO 2015

DIRECTOR BREAST CLINICAL TRIALS UNIT, MOUNT HOSPITAL

BREAST CANCER-SPECIFIC MEDICAL ONCOLOGIST, MOUNT HOSPITAL

- * Breast cancer-specific oncologist
- * Teaching responsibilities
- * FRACP candidates, Advanced trainees in Medical Oncology

1997 TO 2003

CONSULTANT MEDICAL ONCOLOGIST ROYAL PERTH HOSPITAL

- * Establishment of and Clinician in charge of Breast Cancer Risk Assessment Clinic
- * Establishment of Royal Perth Hospital-based Cancer Registry
- * Teaching responsibilities
- * 4th and 5th year Medical students
- * FRACP candidates' tutorials and mock examinations
- * Research activities:
- * Fatigue during chemotherapy in breast and colorectal cancer patients
- * Dose delivery of chemotherapy in breast cancer
- * Establishment of departmental chemotherapy database

1996 - 1997 CLINICAL FELLOWSHIP IN MEDICAL ONCOLOGY

PRINCESS MARGARET HOSPITAL, TORONTO, CANADA

A) Research

- * Biological effect of mammalian lignans on the primary tumour in women with breast cancer
- * Review of 1102 women with primary breast cancer diagnosed under age 36yrs

- * Study of effects of pregnancy on women previously diagnosed with breast cancer under the age of 36 years
- * Evaluation of quality of life and communication between patients and physician in patients with metastatic colorectal cancer receiving 5FU and folinic acid

B) Teaching responsibilities

- * Final year medical students
- * Preceptorship Program

1995 MEDICAL ONCOLOGIST (SESSIONAL)

CITY HOSPITAL, NOTTINGHAM, UNITED KINGDOM

- * Establishment of Familial Ovarian Clinic database
- * Clinical assessment of high-risk patients
- * Counselling and education of patients on screening program

1994 MATERNITY LEAVE

1993 MEDICAL ONCOLOGIST (SESSIONAL)

REPATRIATION GENERAL HOSPITAL, Heidelberg, Victoria Australia

1992 MEDICAL ONCOLOGY ADVANCED TRAINEE

REPATRIATION GENERAL HOSPITAL, Heidelberg, Victoria Australia

1991 MEDICAL ONCOLOGY - PALLIATIVE CARE RESEARCH FELLOW

AUSTIN HOSPITAL, Heidelberg, Victoria Australia

(A) Research

Masters of Medicine thesis: Assessment of total palliative care needs in patients with advanced malignancy

(B) Clinical responsibilities

Palliative Medicine Consultant (Sessional) for the Mid Eastern Palliative Care Association

1990 MEDICAL ONCOLOGY - PALLIATIVE CARE RESEARCH FELLOW

AUSTIN HOSPITAL, Heidelberg, Victoria Australia

(A) Research

- Retrospective assessment of Palliative Care in the Austin Hospital
Analysis of the treatment of malignant bowel obstruction due to carcinomatosis, comparing surgical and conservative management
- Venous thrombosis in patients with disseminated malignancy
- Evaluation of patient needs in a community-based Palliative Care Service.

- Upper gastrointestinal bleeding in patients with cancer
- Design and preparatory work for Prospective Palliative Care study

(B) Clinical responsibilities:

Palliative Medicine Consultant (Sessional) for the Mid Eastern Palliative Care Association

1989 MEDICAL ONCOLOGY-HAEMATOLOGY ADVANCED TRAINEE

AUSTIN HOSPITAL, Heidelberg, Victoria, Australia

Teaching responsibilities

- * Clinical tutor to Final year medical students
- * Clinical tutor to FRACP part I candidates
- * Lectures to nursing staff on various aspects of Oncology

1987- 1988 MEDICAL REGISTRAR

REPATRIATION GENERAL HOSPITAL, Heidelberg, Victoria, Australia

1984 -1986 INTERNSHIP, JUNIOR & SENIOR RESIDENT

AUSTIN HOSPITAL, Heidelberg, Victoria, Australia

POST-GRADUATE SUPERVISION

2018

- Christopher Lomma – Medical Oncology Advanced trainee supervisor

2017 TO CURRENT

- Naomi Brook – PhD Supervision “Can oestrogen-dependent and -independent breast cancer metastasis to bone be averted by the potent anti-metastatic protein pigment epithelium-derived factor (PEDF)?”, Curtin University

2015

- Naomi Brook – Masters in Biomedical Research: Mechanisms of chemoresistance in breast cancer, Curtin University
- Briony Clarke – Honours in Biomedical Research: Establishing the prognostic importance of key immune suppressor molecules in tumours and lymph nodes of patients with Luminal B Breast Cancer, Curtin University

2009

- Caroline Bulsara PhD: The role of empowerment in the wellbeing of cancer patients

ABSTRACTS

1. Chan A, Woodruff RK. Palliative Cancer Therapies: Do patients understand them and are they of benefit? Abstract presented at **Goals of Palliative Cancer Therapies, International Workshop Germany March 1992**.
2. Chan A, Woodruff RK. Palliative Care in a Multicultural Society: a Comparison of the Palliative Care Needs of English and Non-English speaking patients. Abstract presented at the **9th International Congress on the Care of the Terminally III. Montreal November 1992**.
3. Jordan L, Woodruff RK, Eicke J, Chan A. Documentation of the Multidisciplinary Nature of the Palliative Care Needs of Patients with Advanced Cancer Abstract presented at the **9th International Congress on the Care of the Terminally III. Montreal November 1992**.
4. Chan A, Woodruff RK, Jordan L, Eicke JP. A prospective assessment of the total palliative care needs of patients with advanced malignancy Poster presentation **National Hospice and Palliative Care Conference 1993 Melbourne**.
5. Woodruff RK, Chan A, Jordan L, Eicke J. Do non-English speaking patients receive sub-optimal palliative care? Abstract in **Clinical Oncology Society of Australia Annual Scientific Meeting, Melbourne Nov 1994**
6. Chan A, Goss P, Pintilli M, Vallis K, Giroud C. A review of 1163 women with early-onset breast cancer ≤ 36 yrs. Poster presentation at **American Society of Clinical Oncology, Denver May 1997**
7. Chan A, Untch M, Petruzelka L, Martin M, Guillem Porta V. Multinational phase II study of Navelbine (N) and Herceptin (H) as first-line therapy for HER2-overexpressing metastatic breast cancer (HER+ MBC) Poster presentation at **25th Annual San Antonio Breast Cancer Symposium Dec 11-14, 2002**
8. Arlene Chan, Janette Saab, Julie-Ann Quayle, Karin Adams on behalf of the Australian Herceptin Expanded Access Program Study Group Clinical efficacy & toxicity of herceptin in metastatic breast cancer patients with tumours that overexpress Her-2 Neu: the Australian Expanded Access Program. Poster presentation at **25th Annual San Antonio Breast Cancer Symposium Dec 11-14, 2002**
9. Boyer M, Gurney H, Rosenthal M, De Souza P, Stockler M, Chan A, Underhill C, McLachlan S, Toner G, McKendrick J Randomised phase II study of gemcitabine (G) with either carboplatin © or docetaxel (D) in patients with locally advanced or metastatic transitional cell carcinoma (TCC) of the urothelium: Preliminary results Poster presentation at **American Society of Clinical Oncology May 31 –June 3 2003**
10. Chan A, Untch M, Petruzelka L, Martin M, Guillem Porta V. Navelbine and Herceptin combination as first line therapy for HER 2- overexpressing metastatic breast cancer (HER2 + MBC) is a highly active and safe regimen. Final results of multinational trial. Poster presentation at **25th Annual San Antonio Breast Cancer Symposium Dec 3-6, 2003**
11. Untch M, Kahlet S, Petruzelka L, Martin M, Guillem Porta V, Gil M, Kellokumpu-Lehtinen P, Aubert D, Gasmi J, Chan A A multinational phase II study of Navelbine (N) and Herceptin (H) as first-line therapy for patients with HER2-positive metastatic breast cancer (HER2+ MBC) Poster presentation **American Society of Clinical Oncology 2004**
12. Chan A, Petruzelka L, Untch M, Martin M, Gil Gil M, V Guillem Porta et al Long term survival of vinorelbine and trastuzumab as first line therapy for Her2-positive metastatic breast cancer patients **J Clin Oncol 2005 23: 587**
13. Eiermann W, Pienkowski T, Crown J, Chap L, Pawlicki M, Martin M, Chan A, Saleh M, Sehdev S, Provencher L, Von Minckwitz G, Semiglazov V, Slamon

- D; Tabah-Fisch I, Buyse M, Riva A, Taupin H, Sauter G, Mackey J, on behalf of the BCIRG 005 Investigators. Phase III randomized trial comparing docetaxel in combination with doxorubicin and cyclophosphamide (TAC) versus doxorubicin and cyclophosphamide followed by docetaxel (AC→T) in Her-2/neu negative early breast cancer patients with positive axillary lymph nodes: Interim analysis of the BCIRG 005 study. **Breast Cancer Research Treat 2005;94(suppl 1):S5**
14. Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Pawlicki M, Chan A, Smylie M, Liu M, Falkson C, Pinter T, Fornander T, Shiftan T, Valero V, Von Minckwitz G, Mackey J, Tabah-Fisch I, Buyse M, Lindsay MA, Riva A, Bee V, Pegram M, Press M, Crown J, on behalf of the BCIRG 006 Investigators. Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC→T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC→TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2 positive early breast cancer patients: BCIRG 006 study **Annual San Antonio Breast Cancer Symposium Dec 8-11, 2005**
 15. Francis P, Green M, GebSKI V, Harvey V, Karapetis C, Chan A, Snyder R, Forbes J. Australian New Zealand Breast Cancer Trials Group, Newcastle, NSW, Australia. Gefitinib has a low clinical benefit rate in advanced breast cancer patients. **Annual San Antonio Breast Cancer Symposium Dec 8-11, 2005**
 16. Pivot X, Koralewski P, Hidalgo J.L, Chan A, Viens P, Schwartzmann G, Brunel E, Ramazeilles C, Assadourian S, Lotz J.P Multicenter Phase 2 Study with RPR116258 in Taxane-resistant Metastatic Breast Cancer (MBC) Patients (pts) **Annual San Antonio Breast Cancer Symposium Dec 8-11, 2005**
 17. Chan A, Metcalf C, Watt P, Longman G, Goldblatt J, Walpole I, Edkins E, Saunders C Prevalence of breast cancer-susceptible mutations in women < 36 years with invasive breast cancer and correlation with histopathology features of the primary cancer **European Breast Cancer Conference March 2006**
 18. A. Chan, N. Tubiana, V. Ganju, P.F. Conte, P. Bougnoux, D. Aubert, T. Bourlard, D. Becquart; Optimal tolerance of an all-oral combination chemotherapy (CT) of oral vinorelbine (NVBo), capecitabine (C) with/without trastuzumab (T) in metastatic breast cancer (MBC) patients (pts) (Abs 10607): Safety Results of two International multicenter studies. **J Clin Oncol 2006 24:10607**
 19. Nicole Tubiana-Mathieu, Philippe Bougnoux, Dominique Becquart, Arlene Chan, Françoise Majois, Marc Espie, Delphine Aubert, Thierry Bourlard, Gustavo Villanova and Pier-Franco Conte Phase II study of an all-oral combination of oral vinorelbine (NVBo) and capecitabine (X) in HER2-negative metastatic breast cancer (MBC): first results of an international phase II trial **Annual San Antonio Breast Cancer Symposium Dec 13-18, 2006**
 20. Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Pawlicki M, Chan A, Smylie M, Liu M, Falkson C, Pinter T, Fornander T, Shiftan T, Valero V, Von Minckwitz G, Mackey J, Tabah-Fisch I, Buyse M, Lindsay MA, Riva A, Bee V, Pegram M, Press M, Crown J, on behalf of the BCIRG 006 Investigators. Phase III randomized trial comparing AC-T with AC-TH) with TCH in the adjuvant treatment of HER2 positive early breast cancer patients: second interim efficacy analysis **Annual San Antonio Breast Cancer Symposium Dec 13-17, 2006**
 21. Chan A, Willsher P, Hastrich D, Ingram D, Anderson J, van der Schaaf A, Thomson J, Joseph D, Redfern A, Latham B, Cartoon S, Provis A, Bulsara M, Millward M Preoperative TAC (Docetaxel, Doxorubicin, Cyclophosphamide) in conjunction with the development of a standard protocol for the management of locally advanced breast cancer **St Gallen's Breast Cancer Oncology Conference March 2007**

22. A Chan Locally advanced breast cancer: need for a co-ordinated multidisciplinary approach **ANZ J Surg 2007:77 (Suppl.1) BS01**
23. A Chan Trastuzumab (Herceptin): Review of adjuvant trials in early breast cancer **ANZ J Surg 2007:77 (Suppl.1) BS04**
24. A. Chan, V. Ganju, D. Becquart, P. Conte, L. Petruzelka, D. Aubert, G. Villanova, N. Tubiana-Mathieu High efficacy of oral vinorelbine (NVBo), capecitabine (X) and trastuzumab (H) triple combination (NVBoXH) in HER2-positive metastatic breast cancer (MBC): first results of an international phase II trial. Abstract 1052 **J Clin Oncol 2007 25: 1052**
25. V. Duric, P. Francis, J. Simard-Lebrun, A. Chan, J. Chirgwin, V. Harvey, A. Sullivan, R. Simes, A. S. Coates, M. Stockler; Preferences for adjuvant chemotherapy (ACT) in early breast cancer: the benefits needed to make extended treatment with docetaxel, doxorubicin, and CMF worthwhile **J Clin Oncol 2007 25:6528**
26. Nicole Tubiana-Mathieu, Philippe Bougnoux, Dominique Becquart, Arlene Chan, Françoise Majois, Marc Espie, Delphine Aubert, Thierry Bourlard, Gustavo Villanova and Pier-Franco Conte Phase II Study Of An All-Oral Combination Of Oral Vinorelbine (Nvbo) And Capecitabine (X) In Her2-Negative Metastatic Breast Cancer (Mbc): First Results Of An International Phase II Trial Abstract 6072 **J Clin Oncol 2007 25:1056**
27. A. Chan, V. Ganju, D. Becquart, P. Conte, L. Petruzelka, D. Aubert, G. Villanova, N. Tubiana-Mathieu High efficacy of oral vinorelbine (NVBo), capecitabine (X) and trastuzumab (H) triple combination (NVBoXH) in HER2-positive metastatic breast cancer (MBC): first results of an international phase II trial. Abstract **European Clinical Cancer Organisation September 2007**
28. Anderson J, Chan A, Thomson J, Taylor D, Bennett M, van der Schaff, Willsher P, Hastrich D, Allpress S Locally advanced breast cancer assessment clinically by MRI and PET after chemotherapy compared with pathological findings **Royal Australian and New Zealand College of Radiologists Annual Scientific Meeting October 2007**
29. Anderson J, Chan A, Thomson J, Taylor D, Bennett M, Van der Schaff, Willsher P, Hastrich, Allpress S Locally advanced breast cancer assessment clinically, by MRI and PET after chemotherapy compared with pathological findings (in press) **Australas Radiol 51 S2 2007**
30. Robert N, Eiermann W, Pienkowski T, Crown J, Martin M, Pawlicki M, Chan A, Bee V, Slamon D, Au H, on behalf of the BCIRG 006 Investigators BCIRG 006: Docetaxel and trastuzumab-based regimens improve DFS and OS over AC-T in node positive and high risk node negative HER2 positive early breast cancer patients: Quality of Life (QOL) at 36 months follow-up **J Clin Oncol 2007:25; 18S:19647**
31. Tubiana-Mathieu N, Bougnoux P, Becquart D, Chan A, Majois F, Espie M, Palumbo R, Llombart A, Villanova G, Conte P All-oral vinorelbine (NVBo) and capecitabine (X) combination for chemotherapy-naïve HER2-negative metastatic breast cancer (MBC) patients: efficacy and safety in an international phase II study **European Breast Cancer Conference Berlin 2008 Abs 412**
32. A. Chan, V. Ganju, D. Becquart, P-F. Conte, L. Petruzelka, L. Goedhals, M. Gil Gil, G. Bernardo, G. Villanova and N. Tubiana-Mathieu First-line trastuzumab (H), oral vinorelbine (NVBo) and capecitabine (X) combination therapy for HER2-positive metastatic breast cancer (MBC): efficacy and safety in a multinational phase II study **European Breast Cancer Conference Berlin 2008 Abs 578**
33. Francis RJ, van der Schaaf AA, Robins P, Tucker K, Thomas EL, Boucek J, Allpress S, Hastrich D, Ingram D, Barham T, Redfern A, Willsher P, Chan A FDG PET imaging to assess response to chemotherapy in Locally Advanced

Breast Cancer (LABC) **Australia and New Zealand Nuclear Medicine Conference, Sydney 2008**

34. Biologic therapy in breast cancer: How far have we come? Royal Australasian College of Surgeons Hong Kong **ANZ Journal of Surgery 2008:78 A2**
35. Adjuvant chemotherapy delivery: Is it all the same? Royal Australasian College of Surgeons Hong Kong April **ANZ Journal of Surgery 2008:78 A2**
36. A. Chan, D. Hastrich, D. Ingram, J. Anderson, T. Barham, A. Van Der Schaaf, D. Joseph, A. Redfern, A. Provis, P. Willsher Final results of XRP6976D: preoperative TAC (docetaxel, doxorubicin, cyclophosphamide) in conjunction with the development of a standard protocol for the management of locally advanced breast cancer **J Clin Oncol 2008 26:628**
37. D. Miles, A. Chan, G. Romieu, L. Y. Dirix, J. Cortes, X. Pivot, P. Tomczak, T. Taran, N. Harbeck, G. G. Steger Randomized, double-blind, placebo-controlled, phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metastatic breast cancer (mBC): AVADO **J Clin Oncol 2008 26:LBA1011**
38. A. Chan, V. Ganju, D. Becquart, P. Conte, M. Gil Gil, L. Petruzelka, G. Bernardo, G. Villanova, N. Tubiana-Mathieu; High Efficacy Of The Combination Chemotherapy (Ct) Of Oral Vinorelbine (Nvbo) And Capecitabine (X) With Trastuzumab (H) In Her2-Positive Metastatic Breast Cancer (Mbc): Updated Analysis Of The Results Of An International Phase II Trial. **European Society of Medical Oncology 2008** Sweden Abstract 904
39. Arlene Chan, Laurence Vanlemmens, Pier F. Conte, Jane Beith, Hellmut Samonigg, Shailendra Verma, Daan ten Bokkel Huinink, Vichien Srimunnimit, Andrea Marton⁹, David W. Miles Efficacy of bevacizumab (BV) plus docetaxel (D) does not correlate with hypertension (HTN) or G-CSF use in patients (pts) with locally recurrent (LR) or metastatic breast cancer (mBC) in the AVADO phase III study. **San Antonio Breast Cancer Symposium Dec 2008 Abst 1027**
40. De Boer RH, Chan A Clinical outcomes of patients with T1N0 breast cancers: how important are biological risk factors? **San Antonio Breast Cancer Symposium Dec 2008 Abst 2078**
41. Chan A, Ganju V, Becquart D, Conte P-F, Petruzelka L, Gil-Gil M, Morand M, Vaissiere N, Villanova G, Tubiana-Mathieu N Multicenter international phase II study of oral vinorelbine (NVBo), capecitabine (X) and trastuzumab (H) triple combination in HER2-positive metastatic breast cancer (MBC): updated results with a longer follow-up. **San Antonio Breast Cancer Symposium Dec 2008 Abst 3151**
42. Tubiana-Mathieu N, Bognoux P, Becquart D, Chan A, Majois F, Espie M, Morand M, Vaissiere N, Villanova G, Conte P-F All-oral combination of oral vinorelbine (NVBo) and capecitabine (X) in HER2-negative metastatic breast cancer (MBC): latest results of a multicenter, international phase II trial with a median follow-up of 37.7 months. **San Antonio Breast Cancer Symposium Dec 2008 Abst 6125**
43. Eiermann W, Pienkowski T, Crown J, Chap L, Pawlicki M, Martin M, Chan A, Saleh M, Sehdev S, Provencher L, Von Minckwitz G, Semiglazov V, Slamon D, Tabah-Fisch I, Buyse M, Riva A, Taupin H, Sauter G, Mackey J BCIRG 005 main efficacy analysis: a phase III randomized trial comparing docetaxel in combination with doxorubicin and cyclophosphamide (TAC) versus doxorubicin and cyclophosphamide followed by docetaxel (ACT) in women with Her-2/neu negative axillary lymph node positive early breast cancer. **San Antonio Breast Cancer Symposium Dec 2008 Abst 77**

44. Arlene Chan, Adrienne Morey HER2 Discordance Between Primary Breast Carcinoma And Locoregional Or Distant Metastatic Disease In Pts Treated In A Single Institution **Cancer Res 2009; 69(24 Suppl): Abst 2024**
45. Arlene Chan, Richard de Boer, Charles Su, Adam Gajdatsy, Andrea Provis, Felicity Osmond, Andrew Whyte Epiphora and eye symptoms in patients treated with docetaxel-based regimens for early stage breast cancer **Cancer Res 2009; 69(24 Suppl): Abst 1119**
46. Harbeck N, Chan A, ten Bokkel Huinink D, Chollet P, Gimenes D, Fabiani C, Salvagni S, Pérez-Michel L, Schneeweiss A, Chlistalla A, Miles DW No clinical evidence for increase in tumour malignant potential in patients (pts) with metastatic breast cancer (mBC) treated with bevacizumab (BV) and docetaxel (D) in the phase III AVADO study. **Cancer Res 2009; 69(24 Suppl):Abst 6086**
47. Richard de Boer, Peter A. Kaufman, Shane White, Paul Mainwaring, Bogda Koczwara, Arlene Chan, Yining Ye, Yu-Nien Sun, Henry Adewoye, Dusan Kotasek Primary analysis of a phase 1b combination study of motesanib with paclitaxel or docetaxel for the treatment of locally recurrent, unresectable or metastatic breast cancer **Cancer Res 2009;69(24 Suppl): Abst 205**
48. Miles D.W, Chan A, Romieu G, Dirix L.Y, Cortés J, Pivot X, Tomczak P, Juozaityte E, Harbeck N, Steger G.G, the BO17708 study group Final overall survival (OS) results from the randomised, double-blind, placebo-controlled, phase III AVADO study of bevacizumab (BV) plus docetaxel (D) compared with placebo (PL) plus D for the first-line treatment of locally recurrent (LR) or metastatic breast cancer (mBC). **Cancer Res 2009;69(24 Suppl): Abst 41**
49. Hyams DM, Chan A, de Oliveira C, Snyder R, Vinholes J, Audeh MW, Alencar V, Lombard J, Mookerjee B, Xu J, Klein P Cediranib in Combination with Fulvestrant in Hormone-Sensitive Metastatic Breast Cancer: A Phase II Randomized Study. **Invest New Drugs. 2013 Jun 26.**
50. Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Rolski J, Chan A, Mackey J, Liu M, Pinter T, Valero V, Falkson C, Fornander T, Shiftan T, Olsen S, Buyse M, Kiskartalyi T, Landreau V, Wilson V, Press M, Crown J, on Behalf of BCIRG006 Investigators Phase III Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Docetaxel (AC→T) with Doxorubicin and Cyclophosphamide Followed by Docetaxel and Trastuzumab (AC→TH) with Docetaxel, Carboplatin and Trastuzumab (TCH) in Her2neu Positive Early Breast Cancer Patients: BCIRG 006 Study **Cancer Res 2009;69(24 Suppl): Abst 62**
51. A Chan, DW Miles, D ten Bokkel Huinink, X Durando, C Fabiani, S Salvagni, L Perez-Michel, A Schneeweiss, N Harbeck Evidence from the Phase III Avado study reveals no increase in tumour malignant potential following treatment of metastatic breast cancer with bevacizumab and docetaxel **European Breast Cancer Conference, Mar 2010 Abst 480**
52. A. Chan, D. Yamamoto, R. Bell; Capecitabine/trastuzumab for the first-line treatment of patients with HER2-positive metastatic breast cancer (MBC). **American Society of Clinical Oncology June 2010 Abst 1139**
53. R Dent, G Lindeman, M Clemons, H Wildiers, A Chan, N McCarthy, E Kubista, E Lowe, K Kemsley J Carmichael Safety and efficacy of the oral PARP inhibitor olaparib (AZD2281) in combination with paclitaxel for the first- or second-line treatment of patients with metastatic triple-negative breast cancer: Results from the safety cohort of a phase I/II multicenter **American Society of Clinical Oncology June 2010 Abst 1018**
54. L. B. Petruzelka, V. Ganju, D. Becquart, P. F. Conte, N. Tubiana-Mathieu, M. J. Gil Gil, M. Morand, N. Vaissiere, G. Villanova, A. Chan Phase II study of the combination of oral vinorelbine (NVBo), capecitabine (X), and trastuzumab (H) in HER2-positive, metastatic breast cancer (MBC): Recent analysis of the

results with a median follow-up of 44 months **American Society of Clinical Oncology June 2010 Abst 1077**

55. J.P. Crown, M. Casey, D. Cameron, A. Chan, C.E. Geyer Lapatinib (L) Plus Capecitabine (C) in HER2-positive Metastatic Breast Cancer (MBC): An Exploratory Analysis of Overall Survival (OS) Based on Post study Therapy **European Society of Medical Oncology Milan 2010 Abst 291P**
56. Chan A, Lewis C, De Boer R Prevalence Of Triple Negative Breast Cancer (TNBC) And Its Management In 3 Large Breast Cancer Centres In Australia: A Retrospective Review **Cancer Res 2010;70;1017**
57. Ted Vandenberg, Shailendra Verma, Syblle Loibl, Jeff Crawford, Mi Rim Choi, Lyndah Dreiling, Arlene Chan Underreporting of myelotoxicity with emerging breast cancer regimens **Cancer Res 2010;70 0130**
58. Miles D, Haas S, Dirix L, Chan A, Pivot X, Tomczak P, Provencher L, Delmar P, Scherer S Plasma biomarker analyses in the AVADO phase III randomized study of first-line bevacizumab + docetaxel in patients with Human Epidermal Growth Factor Receptor (HER) 2-negative metastatic breast cancer **Cancer Res 2010;70**
59. P. E. Goss, C. H. Barrios, A. Chan, S. K. Chia, S. Delaloge, B. Ejlersen, J. N. Ingle, B. Moy, H. Iwata, F. A. Holmes, J. Mansi, G. Von Minckwitz, L. Han, A. Thiele, V. Agrapart, A. Freyman, J. Truscello, A. Berkenblit, D. Finkelstein A phase III trial of adjuvant neratinib (NER) after trastuzumab (TRAS) in women with early-stage HER2+ breast cancer (BC). **J Clin Oncol** 29: 2011 (suppl; abstr TPS137)
60. DW Miles, SL De Haas, G Romieu, A Chan, L Dirix, J Cortes, PR Delmar, SJ Scherer Polymorphism analysis in the AVADO randomised phase iii trial of first-line bevacizumab combined with docetaxel in HER2-negative metastatic breast cancer **European Multidisciplinary Cancer Congress, Stockholm, Sept 2011 Abst 1423**
61. Chan A, McGregor S Utilisation of primary and secondary G-CSF prophylaxis enables optimal dose delivery of standard adjuvant chemotherapy in early breast cancer: results of 1655 patients from a single institution **San Antonio Breast Cancer Symposium Dec 2011 Abst 851561**
62. Arlene Chan, Stephen Chan, David Price, Jonas Berg, Ana Luch, Andrew Redfern, Jacqui Chirqwin, Elisabet Lidbrink, Amandeep Dhadha, Jose Lopez-Vega, Henrik Lindman, Jane Beith, Sally Baron-Hay, Astrid Kiermaier, Fabian Herbs, Ian Ellis, Feasibility and Patient Safety of Serial Biopsies (bx) in Metastatic HER2-Positive Breast Cancer (BC) To Evaluate Alterations in Molecular Biomarkers (BM): Preliminary Results of SHERsig (Study of HER2 Signature in Metastatic Breast Cancer) a Prospective Phase II Study. **San Antonio Breast Cancer Symposium Dec 2011 Abst 850856**
63. L Gianni, G Romieu, M Lichinitser, S Serrano, M Mansutti, X Pivot, I Smirnova, A Moliterni, F Andre, A Chan, O Lipatov, S Chan, A Wardley, R Greil, L Provencher, N Moore, S Prot, V Semiglazov First results of AVEREL, a randomized phase III trial to evaluate bevacizumab (BEV) in combination with trastuzumab (H) + docetaxel (DOC) as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer (LR/mBC) **San Antonio Breast Cancer Symposium Dec 2011 Late breaking Abstract**
64. L Gianni, A Chan, M Mansutti et al Biomarker results from the Phase III Averal trial of first-line bevacizumab, trastuzumab + docetaxel for HER2-positive locally recurrent/metastatic breast cancer **European Society of Medical Oncology September 2012 Abst 1657**
65. S Cinieri, A Chan, K Altundag, N Tubiana-Mathieu, Bamadas A, P Dodyk, S Lazzarelli, M Botha, G Villanova, U Coskun Final results of an international three-arm randomised phase II study evaluating oral vinorelbine plus capecitabine versus paclitaxel plus gez versus docetaxel plus gemcitabine as

- first-line chemotherapy in patients with metastatic breast cancer (NorCap – CA223 trial) **European Cancer Organisation 2013 Amsterdam Abstract 078**
66. Goss PE, Barrios CH, Chan A, et al. Denosumab versus placebo as adjuvant treatment for women with early-stage breast cancer at high risk of disease recurrence (D-CARE): An international, placebo-controlled, randomized, double-blind phase III clinical trial [abstract]. *J Clin Oncol.* 2013;13. Abstract TPS662.
 67. Miguel Martín, Norberto Batista, Mikhail Shtivelband, Arlene Chan, Suzette Delalogue, Luc Dirix, Soo Chin Lee, Sylvie Le Mouhaer, Sandrine Nanni, Emmanuelle DiTomaso, Patrick Urban, Joyce O'Shaughnessy Buparlisib (BKM120), an oral pan-PI3K inhibitor, in combination with paclitaxel in patients with HER2-negative, locally advanced or metastatic breast cancer, with or without PI3K pathway activation: A Phase II, randomized, double-blind, placebo-controlled study – BELLE-4 **San Antonio Breast Cancer Symposium Dec 2013**
 68. Chan A, O'Carrigan B, McGregor S, Beith J Central nervous system metastases in breast cancer: Impact of tumour sub-type and outcome from current treatments **San Antonio Breast Cancer Symposium Dec 2013**
 69. Goss PE, Barrios CH, Chan A, Finkelstein DM, Iwata H, Martin M, Braun A, Zhou Y, Maniar T, Coleman RE Denosumab versus placebo as adjuvant treatment for women with early-stage breast cancer at high risk of disease recurrence (D-CARE): A global, placebo-controlled, randomized, double-blind, phase 3 clinical trial **San Antonio Breast Cancer Symposium Dec 2013**
 70. S. Cinieri, A. Chan, K. Altundag, A Vandebroek, N. Tubiana-Mathieu, A. Barnadas, P. Dodyk, S. Lazzarelli, M. Botha, D. Rauch, R. Khasanov, C.F. Slabber, P. Bougnoux, J. Cardenas, J. Castellanos, H. Kolbl, M.J. Gode, D. Chen, G. Villanova, U Coskun. Three-arm randomised phase II study evaluating oral vinorelbine plus Capecitabine versus paclitaxel plus gemcitabine versus docetaxel plus gemcitabine as first-line chemotherapy in patients with metastatic breast cancer: final results (NorCap-CA223 trial) **American Society of Clinical Oncology June 2014**
 71. Arlene Chan, Suzette Delalogue, Frankie Ann Holmes, Beverly Moy, Hiroji Iwata, Vernon Harvey, Nicholas Robert, Tajana Silovski, Erhan Gokmen, Gunter von Minckwitz, Bent Ejlersen, Stephen Chia, Janine Mansi, Carlos Barrios, Michael Gnant, Alvin Wong, Richard Bryce, Bin Yao, Miguel Martin Neratinib after adjuvant chemotherapy and trastuzumab in HER2-positive early breast cancer: Primary analysis at 2 years of a phase 3, randomized, placebo-controlled trial (ExteNET) **Oral Presentation Abst 508 American Society of Clinical Oncology Chicago June 2015**
 72. Arlene Chan, Miguel Martin, Gunter von Minckwitz, Bent Ejlersen, Stephen Chia, Marc Buyse, Janine Mansi, Michael Gnant, Frankie Ann Holmes, Beverly Moy, Hiroji Iwata, Alvin Wong, Alshad Lalani, Richard Bryce, Judith Bechuk, Suzette Delalogue
Invasive disease-free survival benefit following neratinib as extended adjuvant therapy in centrally-confirmed HER2+ early-stage breast cancer: The ExteNET phase III randomized placebo-controlled trial ORAL PRESENTATION Abst 117 Breast Cancer Symposium, San Francisco June 2015
 73. Andrew Redfern, Sally A McLaren, Vijani Dissanayake, Arlene Chan, N Zeps, Alexander Dobrovic, Lilian Soon, Erik W Thompson and Christobel M Saunders Predictive value of de novo and induced epithelial-mesenchymal transition in locally advanced breast cancer treated with neoadjuvant chemotherapy **San Antonio Breast Cancer Symposium Dec 2015**
 74. Randomized Phase 2, Open-Label, Dose-Ranging Study of SPI-2012 or Pegfilgrastim for the Management of Neutropenia in Patients with Early Stage Breast Cancer (ESBC) receiving Adjuvant or Neoadjuvant Chemotherapy with

Docetaxel + Cyclophosphamide (TC) **San Antonio Breast Cancer Symposium 2015**

75. Miguel Martín, Arlene Chan, Luc Dirix, Joyce O'Shaughnessy, Roberto Hegg, Alexey Manikhas, Mikhail Shtivelband, Petr Krivorotko, Norberto Batista López, Mario Campone, Manuel Ruiz Borrego, Qamar J. Kahn, J. Thaddeus Beck, Manuel Ramos Vasquez, Patrick Urban, Pantelia Roussou, Emmanuelle Di Tomaso, Cristian Massacesi, Suzette Delalogue BELLE-4: A Phase II study of buparlisib and paclitaxel in women with HER2– advanced breast cancer, with or without PI3K pathway activation **AACR-NCI-EORTC International Conference, Boston 2015**
76. Redfern AD, McLaren SA, Dissanayake V, Chan A, Zeps N, Dobrovic A, Soon L, Thompson EW, Christobel SM Predictive value of de novo and induced epithelial-mesenchymal transition in locally advanced breast cancer treated with neoadjuvant chemotherapy P1-0503 **San Antonio Breast Cancer Symposium 2015**
77. Vacirca JL, Chan A, Mezei K, Adoo CS, Papai Z, McGregor K, Okera M, Horvath Z, Landherr L, Hanslik J, Hager SJ, Ibrahim EN, Ghazal H, Rostom M, Bhat G, Choi MR, Allen LF, Tedesco KL, Agajanian R, Lang I Randomized phase 2, open-label, dose-ranging study of a novel, long-acting G-CSF (SPI-2012) or pegfilgrastim for the management of neutropenia in patients with breast cancer (BC) treated with (Neo) adjuvant chemotherapy with docetaxel + cyclophosphamide (TC) P1-10-05 **San Antonio Breast Cancer Symposium 2015**
78. Slamon DJ, Eiermann W, Robert NJ, Giermek J, Martin M, Jasiowka M, Mackey JR, Chan A, Liu M-C, Pinter T, Valero V, Falkson C, Fornander T, Shiftan TA, Bensfia S, Hitier S, Xu N, Bée-Munteanu V, Drevot P, Press MF, Crown J. Ten year follow-up of the BCIRG-006 trial comparing doxorubicin plus cyclophosphamide followed by docetaxel (AC®T) with doxorubicin plus cyclophosphamide followed by docetaxel and trastuzumab (AC®TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2+ early breast cancer patients **Oral Presentation San Antonio Breast Cancer Symposium 2015**
79. Arlene Chan, Suzette Delalogue, Frankie Ann Holmes, Beverly Moy, Hiroji Iwata, Vernon Harvey, Nicholas Robert, Tajana Silovski, Erhan Gokmen, Gunter von Minckwitz, Bent Ejlersen, Stephen Chia, Janine Mansi, Carlos Barrios, Michael Gnant, Alvin Wong, Richard Bryce, Bin Yao, Miguel Martin Neratinib after trastuzumab-based adjuvant therapy in early-stage HER2+ breast cancer: 3-year analysis from a phase 3 randomized, placebo-controlled, double-blind trial (ExteNET) **Oral Presentation San Antonio Breast Cancer Symposium 2015**
80. Fabrice André, Salomon M. Stemmer, Gabriel N. Hortobagyi, Howard A. Burris, Shani Paluch-Shimon, Mario Campone, Cristian Villanueva, Arlene Chan, Erik Wist, Norbert Marschner, Thomas Bachelot, Sibel Blau, Wolfgang Janni, Sunil Verma, Pierfranco Conte, Shyeilla Dhuria, Shu Yang, Mario Stegert, Caroline Germa, Carlos L. Arteaga Ribociclib + letrozole for first-line treatment of HR+, HER2– ABC: efficacy, safety, and pharmacokinetics **EORTC-NCI-AACR, 2016**
81. Howard A. Burris, Arlene Chan, Mario Campone, Kimberly L. Blackwell, Eric P. Winer, Wolfgang Janni, Sunil Verma, Olga Burdaeva, Emilio Alba, Anne M. Favret, Shoubhik Mondal, Michelle Miller, Caroline Germa, Samit Hirawat, Yoon Sim Yap First-line ribociclib + letrozole in patients with HR+, HER2– advanced breast cancer presenting with visceral metastases or bone-only disease: A subgroup analysis of the MONALEESA-2 trial Abstract P4-22-16 **San Antonio Breast Cancer Symposium 2016**
82. Carlos H. Barcenas, Emad Ibrahim, Mary Wilkinson, Sara Hurvitz, Nicholas Iannotti, Andrew Kellum, Yvonne Manalo, Serena Wong, Vincent Hansen,

- Ricardo H. Alvarez, Arlene Chan, Ira Gore, S. DiSean Kendall, James L. Wade III, Elizabeth Olek, Daniel Hunt, Pearl Fang, Azita Ebtahaj, Rico Ustaris, Susan Moran, Debu Tripathy Incidence and severity of diarrhea with neratinib plus intensive loperamide prophylaxis in patients with HER2-positive early-stage breast cancer: interim analysis from the multicenter, open label, phase II CONTROL Abstract P4-11-03 **San Antonio Breast Cancer Symposium 2016**
83. Fabrice André, Salomon M. Stemmer, Gabriel N. Hortobagyi, Howard A. Burris, Shani Paluch-Shimon, Mario Campone, Cristian Villanueva, Arlene Chan, Erik Wist, Norbert Marschner, Thomas Bachelot, Sibel Blau, Wolfgang Janni, Sunil Verma, Pierfranco Conte, Shyeilla Dhuria, Shu Yang, Mario Stegert, Caroline Germa, Carlos L. Arteaga Ribociclib + letrozole for first-line treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): efficacy by baseline tumor markers Clinical Trials Plenary Session at the **2017 AACR Annual Meeting in Washington, DC**
84. Ibrahim E, Tripathy D, Wilkinson M, Hurvitz S, Iannotti N, Kellum A, Manalo Y, Wong S, Hansen V, Alvarez RH, Chan A, Gore I, Kendall SD, Wade JL, Olek E, Hunt D, Fang P, Ebtahaj A, Barcenas CH Effects of adding budesonide or colestipol to loperamide prophylaxis on neratinib-associated diarrhea in patients with HER2+ early-stage breast cancer: the CONTROL trial **2017 AACR 110th Annual Meeting Washington DC, USA**
85. Barrios C, Somali I, Smichkoska S, Kim S-B, Wong ,5 Xu F, Chan A Mechanism of action of neratinib: an irreversible pan-HER inhibitor in late-stage clinical development **2017 Oncology Nursing Society (ONS) Congress, Denver, CO, USA**
86. Wolfgang Janni, Howard A. Burris, Kimberly L. Blackwell, Lowell L. Hart, Arlene Chan, Arnd Nusch, Olga Burdaeva, Emilio Alba, Denise A. Yardley, Thomas Bachelot, Miguel Gil-Gil, Donald Richards, Joseph Sparano, Joseph Kattan, Hugues Bourgeois, Fadi Karak, Bhuvanewari Ramaswamy, Santosh Sutradhar, Michelle Miller Pierfranco Conte First-line ribociclib plus letrozole for postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC): MONALEESA-2 safety results **Abst American Society of Clinical Oncology Chicago June 2017**
87. Delalogue S, Ye Y, Cella D, Buyse M, Chan A, Barrios CH, Holmes FA, Mansi J, Iwata H, Ejlersen B, Moy B, von Minckwitz G, Chia S Effects of neratinib on health-related quality of life (HRQoL) in early-stage HER2+ breast cancer: longitudinal analyses from the phase III ExteNET trial **Abst European Society Medical Oncology Congress Madrid September 2017**
88. Neratinib after trastuzumab (T)-based adjuvant therapy in early-stage HER2+ breast cancer (BC): 5-year analysis of the phase III ExteNET trial M. Martin Jimenez F. Holmes B. Ejlersen S. Delalogue B. Moy H. Iwata G. Von Minckwitz S. Chia J. Mansi C. Barrios M. Gnant Z. Tomasevic N. Denduluri R. Separovic S. Kim E. Jakobsen R. Bryce F. Xu M. Buyse A. Chan **Oral presentation European Society Medical Oncology Congress Madrid September 2017**
89. First-line Ribociclib + Letrozole for Postmenopausal Women With HR+, HER2- Advanced Breast Cancer: MONALEESA-2 Safety and Health-related Quality of Life Results Wolfgang Janni, Arlene Chan, Arnd Nusch, Emilio Alba,4Thomas Bachelot, Miguel Gil-Gil, Joseph Kattan, Hugues Bourgeois, Fadi El Karak, Santosh Sutradhar, Michelle Miller, David Chandiwana, Pierfranco Conte **Abst ABC4 Lisbon, Portugal November 2017**
90. Chia SKL, Martin M, Iwata H, Moy B, Lalani AS, Holmes FA, Mansi J, von Minckwitz G, Buyse M, Delalogue S, Ejlersen B, Yao B, Murias Rosales A, Hellerstedt B, Cold S, Inoue K, Shen Z-Z, Galeano T, Barrios CH, Chan A Effects of neratinib after trastuzumab-based adjuvant therapy in hormone

receptor-positive HER2+ early-stage breast cancer: Exploratory analyses from the phase III ExteNET trial **Abstract 13-03 40th San Antonio Breast Cancer Symposium 2017**

91. Ejlertsen B, Chan A, Gnant M, von Minckwitz G, Delaloge S, Buyse M, O'Shaughnessy J, Mansi J, Moy B, Iwata H, Wong A, Ye Y, Means-Powell J, Hui R, Ruiz-Borrego M, Ruiz Simon A, Shen Z-Z, Holmes FA, Lesniewski-Kmak K, Martin M Timing of initiation of neratinib after completion of trastuzumab-based adjuvant therapy in early-stage HER2+ breast cancer: Exploratory analyses from the phase III ExteNET trial **Abstract 13-05 40th San Antonio Breast Cancer Symposium 2017**
92. Iwata H, Masuda N, Kim S-B, Inoue K, Rai Y, Fujita T, Shen Z-Z, Chiu JW, Ohtani S, Takahashi M, Yamamoto N, Miyaki T, Sun Q, Yen-Shen L, Xu B, Yap YS, Bustam AZ, Lee JR, Zhang B, Bryce R, Chan A Neratinib in the extended adjuvant treatment of patients from Asia with early-stage HER2+ breast cancer after trastuzumab-based therapy: Exploratory analyses from the phase III ExteNET trial **Abstract 13-011 40th San Antonio Breast Cancer Symposium 2017**
93. Hurvitz S, Chan A, Iannotti N, Ibrahim E, Chien J, Chan N, Kellum A, Hansen V, Marx G, Kendall SD, Wilkinson M, Castrellon A, Ruiz R, Fang P, Hunt D, Moran S, Olek E, Barcenas CH, Rugo HS Effects of adding budesonide or colestipol to loperamide prophylaxis on neratinib-associated diarrhea in patients with HER2+ early-stage breast cancer: The CONTROL trial **Abstract 14-01 40th San Antonio Breast Cancer Symposium 2017**
94. Chia SKL, Martin M, Holmes FA, Ejlertsen B, Delaloge S, Moy B, Iwata H, von Minckwitz G, Mansi J, Barrios CH, Gnant M, Tomašević Z, Denduluri N, Šeparović R, Kim S-B, Hugger Jakobsen E, Harvey V, Robert N, Smith II J, Harker G, Lalani AS, Zhang B, Eli LD, Buyse M, Chan A PIK3CA alterations and benefit with neratinib after trastuzumab-based adjuvant therapy in early-stage HER2+ breast cancer: Correlative analyses of the phase III ExteNET trial **Abstract 3-12 40th San Antonio Breast Cancer Symposium 2017**
95. Hortobagyi GN, Stemmer S, Campone M, Sonke GS, Arteaga CL, Paluch-Shimon S, Petrakova K, Villanueva C, Nusch A, Grischke E-M, Chan A, Jakobsen E, Marschner N, Hart LL, Alba E, Ohnstand HO, Blau S, Yardley DA, Solovieff N, Su F, Germa C, Yap Y-S First-line ribociclib + letrozole in hormone receptor-positive, HER2-negative advanced breast cancer: Efficacy by baseline circulating tumor DNA alterations in MONALEESA-2 **Abstract 4-06 40th San Antonio Breast Cancer Symposium 2017**
96. Frankie Ann Holmes, Arlene Chan, Noelia Martinez, John S. Link, Julie Means-Powell, Søren Cold, Kenichi Inoue, Yining Ye, Susan Moran, Miguel Martin Neratinib after trastuzumab-based adjuvant therapy in early-stage HER2+ breast cancer: 5-year efficacy findings from the randomized phase III ExteNET trial **Abstract 633 Miami Breast Meeting 2018**
97. Michael Gnant, Arlene Chan, Duration of extended adjuvant therapy with neratinib in early-stage HER2+ breast cancer after trastuzumab-based therapy: Exploratory analyses from the phase III ExteNET trial **Abstract 524 American Society of Clinical Oncology Chicago June 2018**
98. Gabriel N. Hortobagyi, Shani Paluch-Shimon, Katarina Petrakova, Cristian Villanueva, Arlene Chan, Arnd Nusch, Yoon-Sim Yap, Lowell Hart, Anne Favret, Norbert Marschner, Gabe S. Sonke, Hege O. Ohnstad, Carlos L. Arteaga, Faye Su, Wei He, Michelle Miller, Salomon M. Stemmer First-line Ribociclib + Letrozole in Hormone Receptor-positive, HER2-negative Advanced Breast Cancer: MONALEESA-2 Biomarker Analyses **Abstract 1022 American Society of Clinical Oncology Chicago June 2018**

99. Peter A. Fasching, Francisco J. Esteva, Xavier Pivot, Arnd Nusch, J. Thaddeus Beck, [Arlene Chan](#), Asanthi Pieris Gunatilaka, Yingbo Wang, Brad Lanoue, David Chandiwana, Patrick Neven Patient-reported outcomes in advanced breast cancer treated with ribociclib + fulvestrant: results from MONALEESA-3 **Abstract Oral European Society of Medical Oncology Conference 2018**
100. Dennis J. Slamon, Patrick Neven, Stephen Chia, Seock-Ah Im, Peter A. Fasching, Michelino De Laurentiis, Katarina Petrakova, Giulia Val Bianchi, Francisco J. Esteva, Miguel Martin, Xavier Pivot, [Arlene Chan](#), Gena Vidam, Yingbo Wang, Karen Rodriguez Lorenc, Michelle Miller, Tetiana Taran, Guy Jerusalem Ribociclib + Fulvestrant in Postmenopausal Women With Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer: Results From MONALEESA-3 **Abstract 193 Melbourne International Joing Breast Congress 2018**
101. Chris Lomma, Peter Willsher, Huijun Chih, [Arlene Chan](#) Male breast cancer in Australia: Compliance with treatment key performance indicators – 99,768 breast cancers over a 10 year period **Abstract Melbourne International Joing Breast Congress 2018**
102. Amali Samarasinghe, [Arlene Chan](#), Diana Hastrich, Richard Martin, Albert Gan, Farah Abdulaziz, Margaret Latham, Yvonne Zissiadis, Mandy Taylor, Peter Willsher Compliance With Multidisciplinary Team Meeting Treatment Recommendations. **Abstract Melbourne International Joing Breast Congress 2018**
103. Trisha Khoo, [Arlene Chan](#), HuiJun Chi, Christopher Reid Vitamin D Level and Breast Cancer Outcome **Abstract Melbourne International Joing Breast Congress 2018**
104. Chris Lomma, Peter Willsher, [Arlene Chan](#) Systemic Adjuvant Treatment Recommendations and Compliance in Australian Patients with Early Breast Cancer **Abstract Melbourne International Joing Breast Congress 2018**
105. Chris Lomma, Peter Willsher, HuiJun Chih, [Arlene Chan](#) Male breast cancer: tumour characteristics and treatment compared with females in Australia – a study of 99,768 episodes of breast cancer over a 10 year period **Abstract 41st San Antonio Breast Cancer Symposium 2018**
106. Chan A, Spera G, Machado A, Fung H, Bee V, Fresco R, Slamon DJ Central nervous system as first site of relapse in patients with HER2 positive early breast cancer treated in the BCIRG-006 trial **Abstract PD3-21 41st San Antonio Breast Cancer Symposium 2018**
107. J Thaddeus Beck, Patrick Neven, Joohyuk Sohn, [Arlene Chan](#), Gabe S. Sonke, Thomas Bachelot, Saul Campos-Gomez, Miguel Martin, Aditya Bardia, Jahangir Alam, Michelle Miller, Ivan Diaz Padilla, Oliver Kong, Lowell Hart Ribociclib treatment benefit in patients with advanced breast cancer with ≥ 1 dose reduction: Data from the MONALEESA-2, -3, and -7 trials **Abstract 41st San Antonio Breast Cancer Symposium 2018**
108. Michael Gnant, Miguel Martin, Frankie-Ann Holmes, Christian Jackisch, Stephen K.L. Chia, Hiroji Iwata, Beverly Moy, Noelia Martinez, Janine Mansi, Serafin Morales, Manuel Ruiz Borrego, Gunter von Minckwitz, Marc Buyse, Suzette Delaloge, Manish Bhandari, Adolfo Murias Rosales, Teresa Galeano, Takashi Fujita, Adam Luczak, Carlos H. Barrios, Cristina Saura, Hope S. Rugo, Jo Chien, Stephen R.D. Johnston, Matthew Spencer, Feng Xu, Brian Barnett, Richard Bryce, [Arlene Chan](#), and Bent Ejlersen Efficacy of neratinib in hormone receptor-positive patients who initiated treatment within 1 year of completing trastuzumab-based adjuvant therapy in HER2+ early stage breast **Abstract 41st San Antonio Breast Cancer Symposium 2018**
109. Delaloge S, Hurvitz S, Chan N, Bose R, Jankowitz RC, Thirlwell M, Láng I, ten Tije A, Trudeau M, Osborne CR, Shen Z-Z, Lalla D, Xu F, Hunt D, Olek E, Tripathy D, Rugo

HS, Chien J, Chan A, Barcenas CH The impact of neratinib with or without anti-diarrheal prophylaxis on health-related quality of life in HER2+ early-stage breast cancer: Analyses from the ExteNET and CONTROL trials **Abstract 41st San Antonio Breast Cancer Symposium 2018**

110. Tripathy D, Hortobagyi G, Chan A, Im S-A, Chia S, Yardley D, Esteva FJ, Hurvitz S, Kong O, Bao W, Rodriguez Lorenc K, Diaz-Padilla I, Slamon DJ First-line ribociclib + endocrine therapy in hormone receptor-positive, HER2-negative advanced breast cancer: A pooled efficacy analysis **Abstract 41st San Antonio Breast Cancer Symposium 2018**
111. Denise A. Yardley, Arlene Chan, Arnd Nusch, Gabe S. Sonke, Yoon-Sim Yap, Thomas Bachelot, Francisco J. Esteva, Dennis J Slamon, Howard A Burris, Anil Gaur, Oliver Kong, Ivan Diaz-Padilla, Karen Rodriguez Lorenc, Paul Wheatley-Price Ribociclib + endocrine therapy in patients with hormone receptor-positive, HER2-negative advanced breast cancer presenting with visceral metastases: Subgroup analysis of phase III MONALEESA trials **Abstract 41st San Antonio Breast Cancer Symposium 2018**
112. Howard A. Burris, Arlene Chan, Seock-Ah Im, Stephen Chia, Debu Tripathy, Francisco J. Esteva, Mario Campone, Aditya Bardia, Juan Pablo Zarate, Weibin Bao, Ivan Diaz-Padilla, Karen Rodriguez Lorenc, Denise A. Yardley Ribociclib + endocrine therapy in hormone receptor-positive, HER2-negative advanced breast cancer: A pooled safety analysis **Abstract 41st San Antonio Breast Cancer Symposium 2018**
113. HuiJun Chih, Arlene Chan, Christopher Reid, Chris Lomma How are the kids? Psychosocial wellbeing and needs of the offspring of breast cancer patients Oral presentation **Behavioural Research in Cancer Control Conference 2019**
114. **American Association of Nurse Practitioners (AANP) 2019 National Conference 2019**

MANUSCRIPTS

- 1) Chan A *Management of Herpes Zoster in general practice* **Mid Eastern Palliative Care Association Newsletter** March 1990
- 2) Chan Arlene, Rischin Danny, Woodruff Roger K, Clarke Charles P *Subxiphoid partial pericardiectomy with or without sclerosant instillation in the treatment of symptomatic pericardial effusions in patients with malignancy* **Cancer** 1991 Sept 68:1021-5
- 3) Chan A, Woodruff RK *Palliative care in a general teaching hospital 1. Assessment of needs* **Medical Journal of Australia** 1991 November 155:597-9
- 4) Woodruff RK, Jordan L, Eicke JP, Chan A *Palliative care in a general teaching hospital 2. Establishment of a service* **Medical Journal of Australia** 1991 November 155: 662-665
- 5) Chan A, Woodruff RK *Intestinal obstruction due to advanced intra-abdominal malignancy* **Journal of Pain and Symptom Management** 1991.7(6):339-342
- 6) Chan A, Woodruff RK *Complications and failure of anticoagulant therapy in the management of venous thromboembolism in patients with disseminated malignancy* **Australian and New Zealand Journal of Medicine** April 1992 22:119-122
- 7) Chan A, Chapman W, Oza A *Unusual presentation of disorder of sexual differentiation* **International Journal of Gynaecological Oncology** 1997 (7) 329-31
- 8) Chan A, Woodruff RK *Communicating with patients with advanced cancer* **Journal of Palliative Care** 1997;13(3) 29-33
- 9) Chan A, Woodruff RK *Comparison of palliative care needs of English- and non-English-speaking patients* **Journal of Palliative Care** 1999 15:26-30
- 10) Chan A, Goss P, Pintilli M, Vallis K, Giroud C *Breast cancer in women \leq 35 years: Review of 1002 cases from a single institution* **Ann Oncol** 2000 11:1255-1262
- 11) Saunders C, Chan A, Wylie E, Khong E *How to Treat Updates in Breast Cancer* **Australian Doctor** June 2004
- 12) Chan A *Clinical Update: Family history and breast cancer* **Medical Forum** September 2004
- 13) Chan A *Clinical Update: Clinical trials in breast cancer* **Medical Forum** December 2004
- 14) Chan A *Herceptin in early breast cancer* **Medical Forum** July 2006
- 15) Gelmon K, Chan A, Harbeck N *The Role of Capecitabine in First-line treatment for patients with metastatic breast cancer* **The Oncologist** 2006;11(suppl)42-51
- 16) Chan A, Martin M, Untch M et al *Vinorelbine plus trastuzumab combination as first-line therapy for HER 2-positive metastatic breast cancer patients: an International Phase II Trial* **British J Cancer** 2006: 95(7):788-93
- 17) Geyer C, David Cameron, Forster J, Lindquist D, Chan S, Romieu C, Pienkowski T, Crown J, Chan A, Kaufman B, et al *Lapatinib plus capecitabine for HER2-positive advanced breast cancer* **New Engl J Medicine** 2006 355:2733-43
- 18) Chan A *Lapatinib – overview and current role in metastatic breast cancer* **Cancer Res Treat** 2006;38(4):198-200
- 19) Chan A *The management of Taxotere-induced febrile neutropenia in breast cancer patients* **International Review of Patient care** Spring 2007: 31-36
- 20) Chan A *A review of the use of trastuzumab (Herceptin[®]) plus vinorelbine in metastatic breast cancer* **Ann Oncol** 2007 18:1152-8
- 21) Bulsara C, Styles, I Chan A *Motivating women with breast cancer to achieve empowerment by the use of support strategies in* **Motivation of Health Behaviour** 2007

- 22) Arlene Chan and Richard de Boer *Use of trastuzumab for metastatic breast cancer in Australia: Inaccurate results and alternative interpretation of findings* Letter to Editor **J Clin Oncol** 2007;25:5662
- 23) Peters G, Anderson J, Longman G, Thomson J, Taylor D, Hua J, Bennett M, Wylie E, Goldblatt J, Chan A, Saunders C *MR-Findings in Patients at High Risk for Developing Breast Cancer* **J Med Imaging Radiat Oncol.** 2008 Feb;52(1):29-35.
- 24) David Cameron, Michelle Casey, Deborah Lindquist, Tadeusz Pienkowski, C. Gilles Romieu, Stephen Chan, Agnieszka Jagiello-Grusfeld, Bella Kaufman, John Crown, Arlene Chan, Mario Campone, Patrice Viens, Vera Gorbunova, Neville Davidson, Dimosthenis Skarlos, Johannes Isaac Raats, Beth Newstat, Debasish Roychowdhury, Paolo Paoletti, Cristina Oliva, Stephen Rubin, Steven Stein, Charles E. Geyer *A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses* **Breast Cancer Res Treat** 2008 112(3):533-43
- 25) Pivot X, Koralewski P, Hidalgo J, Chan A, Gonçalves A, Schwartzmann G, Assadourian S, Lotz J *A multicenter phase II study of XRP6258 administered as a 1-h i.v. infusion every 3 weeks in taxane-resistant metastatic breast cancer patients* **Ann Oncol.** 2008;19(9):1547-52
- 26) Peters G, Anderson J, Longman G, Thomson J, Taylor D, Bennett M, Wylie E, Goldblatt J, Chan A, Saunders C *Magnetic resonance findings in women at high risk for developing breast cancer: An Australian feasibility study* **J Med Imaging Radiat Oncol** 2008 52:29-35
- 27) Saunders CM, Peters G, Longman G, Thomson J, Taylor D, Hua J, Bennett M, Wylie E, Goldblatt J, Chan A, Anderson J *A pilot study of trimodality breast imaging surveillance in young women at high risk of breast cancer in Western Australia* **Med J Aust.** 2009 Sep 21;191(6):330-3
- 28) Chan A *Antiangiogenic therapy for metastatic breast cancer: Current status and future directions* **Drugs** 2009 69(2):167-181
- 29) Snyder R, Boyle F, Chan A, Craft P, de Boer R, Mainwaring P, McCarthy N, Wilcken N *Clinical recommendations for the use of lapatinib ditosylate plus capecitabine for patients with advanced or metastatic HER-positive breast cancer* **Asia-Pacific J Clin Oncol** 2009 5:4-16
- 30) Nicole Tubiana-Mathieu, Philippe Bounoux, Dominique Becquart, Arlene Chan, Pier-Franco Conte, Françoise Majois, Marc Espie, Maryse Morand, Nathalie Vaissière and Gustavo Villanova *All-oral combination of oral vinorelbine and capecitabine as first-line chemotherapy in HER2-negative metastatic breast cancer: an International Phase II Trial* **Br J Cancer** 2009 101(2) 232-7
- 31) M. Green, P.A. Francis, V. Gebski, V. Harvey, C. Karapetis, A. Chan, R. Snyder, A. Fong, R. Bassar, J. Forbes on behalf of the Australian New Zealand Breast Cancer Trials Group *Gefitinib treatment in hormone resistant and hormone receptor negative advanced breast cancer* **Ann Oncol** 2009 20:1813-1817
- 32) Arlene Chan, Richard De Boer, Jane Beith, David Grimes, Dusan Kotasek, Nicholas Wilcken *Clinical controversies in breast cancer: A thought leader forum and consensus roundtable* **Asia Pacific J Oncology and Haematology** 2009 1(3):1-7
- 33) Arlene Chan, Mark Verrill *Capecitabine and vinorelbine in metastatic breast cancer* **Eur J Cancer** 2009 45:2253-2265
- 34) David W. Miles, Arlene Chan, Luc Y. Dirix, Javier Cortés, Xavier Pivot, Piotr Tomczak, Thierry Delozier, Joo Hyuk Sohn, Louise Provencher, Fabio Puglisi, Nadia Harbeck, Guenther Steger, Andreas Schneeweiss, Andrew M. Wardley, Andreas Chlistalla, and Gilles Romieu *Phase III Study of Bevacizumab Plus*

- Docetaxel Compared With Placebo plus Docetaxel for the First-line Treatment of HER2-Negative Metastatic Breast Cancer* **J Clin Oncol** 2010 28:3239-3247
- 35) A Chan, DW Miles, X Pivot *Bevacizumab in combination with taxanes for the first-line treatment of metastatic breast cancer* **Ann Oncol** 2010 21(12):2305-15
- 36) Charles Vogel, Arlene Chan, Brunilde Gril, Sung-Bae Kim, Junichi Kurebayashi, Li Liu, Yen-Shen Lu, Hanlim Moon *Management of ErbB2-positive breast cancer – insights from preclinical and clinical studies with lapatinib* **Japanese Journal of Clinical Oncology** 2010 40(11):999-1013
- 37) Dennis Slamon, Wolfgang Eiermann, Nicholas Robert, Tadeusz Pienkowski, Miguel Martin, Michael Press, John Mackey, John Glaspy, Arlene Chan, Marek Pawlicki, Tamas Pinter, Vicente Valero, Mei-Ching Liu, Guido Sauter, Gunter Von Minckwitz, Frances Visco, Valerie Bee, Marc Buyse, Belguendouz Bendahmane, Isabelle Tabah-Fisch, Mary-Ann Lindsay, Alessandro Riva, John Crown *Adjuvant Trastuzumab in HER2-Positive Breast Cancer* **New Engl J Medicine** 2011:365:1273-1283
- 38) Richard H. de Boer, Arlene Chan, Ben Tran, Nicholas Wilcken *Use of non-anthracycline regimens in early stage breast cancer within Australia* **Asia Pacific J Oncology and Haematology** 2011;7:4-10
- 39) Wolfgang Eiermann, Tadeusz Pienkowski, John Crown, Saeed Sadeghi, Marek Pawlicki, Miguel Martin, Arlene Chan, Mansoor Saleh, Sandeep Sehdev, Louise Provencher, Vladimir Semiglazov, Michael Press, Guido Sauter, Steve Olsen, Mary-Ann Lindsay, Alessandro Riva, Marc Buyse, Henry Taupin, John R. Mackey Phase III study of doxorubicin/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with HER2-normal, node-positive breast cancer: Breast Cancer International Research Group (BCIRG)-005 Trial **J Clin Oncol** 2011:3877-3884
- 40) Arlene Chan, Shailendra Verma, Sibylle Loibl, Jeffrey Crawford, Mi Rim Choi, Lyndah Dreiling, Ted Vandenberg *Reporting of myelotoxicity associated with emerging regimens for the treatment of selected solid tumors* **Critical Review in Hematology/Oncology** 2012 81:136-150
- 41) Jonas Bergh, Igor M Bondarenko, Mikhail R Lichinitser, Annelie Liljegren, Richard Greil, Nataliya L Voytko, Anatoly N Makhson, Javier Cortes, Alain Lortholary, Joachim Bischoff, Arlene Chan, Suzette Delaloge, Xin Huang, Kenneth A Kern, Carla Giorgetti *First-line treatment of advanced breast cancer with sunitinib in combination with docetaxel versus docetaxel alone – results of a prospective, randomized Phase III study* **J Clin Oncol** 2012 30:921-929
- 42) Arlene Chan, Peter C Willsher, Diana J Hastrich, James Anderson, Tony Barham, Bruce Latham, Andrew Redfern, Agatha van der Schaaf, Jacqui Thomson, David Joseph, David Ingram *Pre-operative taxane-based chemotherapy in a standardized protocol for the management of locally advanced breast cancer* **Asia-Pacific J Clin Oncol** 2012 8(1) 62-70
- 43) Richard H. De Boer Dusan Kotasek, Shane White, Bogda Koczwara, Paul Mainwaring, Arlene Chan, Rebeca Melara, Yining Y, Adeboye H Adewoye, Robert Sikorski, Peter A. Kaufman *Phase 1b dose-finding study of motesanib with docetaxel or paclitaxel in patients With Metastatic Breast Cancer* **Breast Can Research and Treatment** 2012 135(1):241-52
- 44) Arlene Chan, Adrienne Morey, Belinda Brown, Diana Hastrich, Peter Willsher, David Ingram *A retrospective study investigating the rate of HER2 discordance between primary breast carcinoma and locoregional or metastatic disease* **BMC Cancer** 2012 12:555
- 45) Chan A, McGregor S *Prevalence and management of HER2/neu positive early breast cancer in a single institution following availability of adjuvant trastuzumab* **Int Med J Australia** 2012 42:267-274
- 46) David M Hyams, Celia de Oliveira, Raymond Snyder, Paula Klein, Jeferson Vinholes, M William Audeh, Victor M Alencar, Janine Lombard, Bijoyesh

- Mookerjee, John Xu, Kathryn Brown, Arlene Chan *Cediranib in combination with fulvestrant in hormone-sensitive metastatic breast cancer: a randomized Phase II study* **Invest New Drugs** 2013 31:1345-54
- 47) Wolff A, Lazar A, Bondarenko I, Garin A, Brincat S, Chow L, Sun Y, Neskovic-Konstantinovic Z, Guimaraes R, Fumoleau P, Chan A, Hachemi S, Strahs A, Cincotta M, Berkenblit A, Krygowski M, Kang L, Moore L, Hayes D *Randomised Phase III placebo-controlled trial of letrozole plus oral temsirolimus as first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancer* **J Clin Oncol** 2013 31:195-202
- 48) Arlene Chan, Charles Su, Richard H. de Boer, and Adam Gajdatsy *Prevalence of excessive tearing in women with early breast cancer receiving adjuvant docetaxel-based chemotherapy* **J Clin Oncol** May 6, 2013;31:2123-2127
- 49) Luca Gianni, Gilles H. Romieu, Michail Lichinitser, Sergio V. Serrano, Mauro Mansutti, Xavier Pivot, Paola Mariani, Fabrice Andre, Arlene Chan, Oleg Lipatov, Stephen Chan, Andrew Wardley, Richard Greil, Nicola Moore, Sylvie Prot, Celine Pallaud, and Vladimir Semiglazov *AVEREL: A randomized Phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer* **J Clin Oncol** 2013 31:1719-1725
- 50) David Cameron, Julia Brown, Rebecca Dent, Christian Jackisch, John Mackey, Xavier Pivot, Guenther G Steger, Thomas Suter, Masakazu Toi, Mahesh Parmar, Rita Laeufle, Young-Hyuck Im, Gilles Romieu, Vernon Harvey, Oleg Lipatov, Tadeusz Pienkowski, Paul Cottu, Arlene Chan, Seock-Ah Im, Peter Hall, Lida Bubuteishvili-Pacaud, Volkmar Henschel, Regula J Deurloo, Celine Pallaud, Richard Bell *Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): Primary results of a randomised, phase 3 trial* **Lancet Oncology** 2013;14:933-42
- 51) Arlene Chan, Pier-Franco Conte, Lubos Petruzelka, Nicole Tubiana-Mathieu, Vinod Ganju, Antonio Llombart, Marc Espie, Françoise Majoi, Miguel Gil Gil, Nathalie Vaissiere and Gustavo Villanova *Phase II study of a triple combination of oral vinorelbine, capecitabine and trastuzumab as first-line treatment in HER2-positive metastatic breast cancer* **Anticancer Research** 2013 33(6):2657-64
- 52) Baselga J, Gomez P, Griel R, Braga S, Climent M, Wardley A, Kaufman B, Stemmer S, Pego A, Chan A, Goeminne J, Graas M, Kennedy J, Gil E, Schneeweiss A, Zubei A, Groos J, Melesinkova H, Awada A et al *Randomized Phase II study of the anti-epidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus cisplatin alone in patients with metastatic triple-negative breast cancer* **J Clin Oncol**. 2013: 2586-2592
- 53) Au HJ, Eiermann W, Robert NJ, Pienkowski T, Crown J, Martin M, Pawlicki M, Chan A, Mackey J, Glaspy J, Pintér T, Liu MC, Fornander T, Sehdev S, Ferrero JM, Bée V, Santana MJ, Miller DP, Lalla D, Slamon DJ; *Translational research in oncology BCIRG 006 trial investigators health-related quality of life with adjuvant docetaxel- and trastuzumab-based regimens in patients with node-positive and high-risk node-negative, HER2-positive early breast cancer: Results from the BCIRG 006 study* **The Oncologist**. 2013;18(7):812-8
- 54) Roopa Lakhanpal, Robin Stuart-Harris, Arlene Chan, Dusan Kotasek, Jane Beith, Katharine Cuff, Patricia Bastick & Clara Lee *Docetaxel and cyclophosphamide as adjuvant chemotherapy for early breast cancer: Primary prophylaxis with G-CSF is required* **Breast Cancer Manage** 2013;2:367-374
- 55) Dent RA, Lindeman GJ, Clemons M, Wildiers H, Chan A, McCarthy NJ, Singer CF, Lowe ES, Watkins CL, Carmichael J *Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancer* **Breast Cancer Res** 2013 Sep 25;15(5)

- 56) Miles D, De Haas S, Dirix L, Romieu G, Chan A, Pivot X, Tomczak P, Provencher L, Cortés J, Delmar P, Scherer S et al *Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer* **Br J Cancer**. 2013;108:1052-60
- 57) Paul E Goss, Kathrin Strasser-Weippl, Brittany L Lee-Bychkovsky, Lei Fan, Junjie Li, Yanin Chavarri-Guerra, Pedro E R Liedke, C S Pramesh, Tanja Badovinac-Crnjevic, Yuri Sheikine, Zhu Chen, You-Lin Qiao, Zhiming Shao, Yi-Long Wu, Daiming Fan, Louis W C Chow, Jun Wang, Qiong Zhang, Shiyong Yu, Gordon Shen, Jie He, Arnie Purushotham, Richard Sullivan, Rajendra Badwe, Shripad D Banavali, Reena Nair, Lalit Kumar, Purvish Parikh, Somasundaram Subramanian, Pankaj Chaturvedi, Subramania Iyer, Surendra Srinivas Shastri, Raghunadhr Rao Digumarti, Enrique Soto-Perez-De-Celis, Dauren Adilbay, Vladimir Semiglazov, Sergey Orlov, Dilyara Kaidarova, Ilya Tsimafeyeu, Sergei Tatishchev, Kirill D Danishevskiy, Marc Hurlbert, Caroline Vail, Jessica St Louis, Arlene Chan *Challenges to effective cancer control in China, India, and Russia* **Lancet Oncology** 2014;15:489-538
- 58) Arlene Chan, Scott McGregor, Wenbin Liang *Utilisation of primary and secondary G-Csf prophylaxis enables maintenance of optimal dose delivery of standard adjuvant chemotherapy for early breast cancer: An analysis of 1655 patients* **The Breast** 2014;23:676-682
- 59) Arlene Chan, Catherine Shannon, Richard De Boer, Sally Baron-Hay, Andrew Redfern, Astrid Bauwens, Paul Craft, Suzanne Webb, Amanda Townsend, Dusan Kotasek *Phase II, open-label trial of lapatinib and vinorelbine in women with previously treated HER2-positive metastatic breast cancer* **Asia-Pacific Journal of Clinical Oncology** 2014;10:368-375
- 60) Tarek Abdel-Fatah, Graham Ball, Andrew Lee, Sarah Pinder, R Douglas Macmillan, Eleanor Cornford, Paul Moseley, Rafael Silverman, James Price, Bruce Latham, David Palmer, Arlene Chan, Ian Ellis, and Steve Chan *Nottingham Clinico-Pathological Response Index (NPRI) after neoadjuvant chemotherapy (Neo-ACT) accurately predicts clinical outcome in locally advanced breast cancer* **Clinical Cancer Research** 2015;21:1052-62
- 61) Sally A McLaren, Vijani Dissanayake, Andrew Redfern, Arlene Chan, Alexander Dobrovic, Lilian Soon, Erik W Thompson and Christobel M Saunders *Correlations of epithelial-mesenchymal transition with outcome for women with locally advanced breast cancer treated with neoadjuvant chemotherapy (in press) 2015*
- 62) José Baselga, Claudio Zamagni, Patricia Gómez, Begoña Bermejo, Shigenori E. Nagai, Bohuslav Melichar, Arlene Chan, László Mángel, Jonas Bergh, Frederico Costa, Henry L. Gómez, William J. Gradishar, Clifford A. Hudis, Bernardo L. Rapoport, Henri Roché, Patricia Maeda, Liping Huang, Gerold Meinhardt, Joshua Zhang, Lee S. Schwartzberg *RESILIENCE: Phase III randomized, double-blind trial comparing sorafenib plus capecitabine with placebo plus capecitabine in locally advanced or metastatic HER2-negative breast cancer* **Clinical Breast Cancer** 2017 **17:585-594**
- 63) John Mackey, Tadeusz Pieńkowski, John Crown, Saeed Sadeghi, Miguel Martin, Arlene Chan, Mansoor Saleh, Sandeep Sehdev, Louise Provencher, Vladimir Semiglazov, Michael F Press, Guido Sauter, Mary-Ann Lindsay, PharmD; Vincent Houé, MSc; Marc Buyse, Philippe Drevot, Simon Hitier, Samira Bensfia, Wolfgang Eiermann *Long-term outcomes after adjuvant treatment of sequential versus combination docetaxel with doxorubicin and cyclophosphamide in node-positive breast cancer - BCIRG-005 randomized trial* **Ann Oncol** 2016: Jun;**27(6):1041-7**
- 64) Arlene Chan, Suzette Delalogue, Frankie A. Holmes, Beverly Moy, Hiroji Iwata, Vernon J. Harvey, Nicholas J. Robert, Tajana Silovski, Erhan Gokmen, Gunter

von Minckwitz, Bent Ejlersen, Stephen K. L. Chia, Janine Mansi, Carlos H. Barrios, Michael Gnant, Marc Buyse, Ira Gore, John Smith II, Graydon Harker, Norikazu Masuda, Katarina Petrakova, Angel Guerrero Zotano, Nicholas Iannotti, Gladys Rodriguez, Pierfrancesco Tassone, Alvin Wong, Richard Bryce, Yining Ye, Bin Yao, Miguel Martin, for the ExteNET Study Group. *Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): A randomized, double-blind, Phase 3 trial* **Lancet Oncology** February 10, 2016; 17(3) 367-377

- 65) Arlene Chan *Neratinib in HER-2-positive breast cancer: results to date and clinical usefulness* **Ther Adv Med Oncol** 2016 8:339-350
- 66) Chan A, Buyse M, Yao B *Neratinib after trastuzumab in patients with HER2-positive breast cancer – Author’s reply* **Lancet Oncology** 2016 17:e176-e177
- 67) Cinieri S, Chan A, Altundag K, Vandebroek A, Tubiana-Mathieu N, Barnadas A, Dodyk P, Lazzarelli S, Botha M, Rauch D, Villanova G, Coskun U *Final results of the randomized Phase II NorCap-CA223 trial comparing first-line all-oral versus taxane-based chemotherapy for HER2-negative metastatic breast cancer* **Clin Breast Cancer** 2016 pii: S1526-8209(16)30169-0
- 68) Arlene Chan *TILs in metastatic breast cancer – no surprises, but more questions* **Lancet Oncology** 2017 18:5-6
- 69) G.N. Hortobagyi, S.M. Stemmer, H.A. Burris, Y.-S. Yap, G.S. Sonke, S. Paluch-Shimon, M. Campone, K.L. Blackwell, F. André, E.P. Winer, W. Janni, S. Verma, P. Conte, C.L. Arteaga, D.A. Cameron, K. Petrakova, L.L. Hart, C. Villanueva, A. Chan, E. Jakobsen, A. Nusch, O. Burdaeva, E.-M. Grischke, E. Alba, E. Wist, N. Marschner, A.M. Favret, D. Yardley, T. Bachelot, L.-M. Tseng, S. Blau, F. Xuan, F. Souami, M. Miller, C. Germa, S. Hirawat, and J. O’Shaughnessy *Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer* **N Engl J Medicine** 2016 Nov 3;375(18):1738-1748
- 70) Arlene Chan *HER2 positive metastatic breast cancer: what happens after first line failure?* **Cancer Forum** 2016:40:3
- 71) Delia J. Nelson, Kylie Munyard, Vincent Williams, David Groth, Jespal Gill, Henry Preston and Arlene Chan *A review of the importance of immune responses in luminal B breast cancer* **Oncoimmunology** 2016 6:e1282590
- 72) Chan A, De Boer R, Gan A, Willsher P, Martin R, Zissiadis Y, Miller K, Bauwens A, Hastrich D *Randomized phase II placebo-controlled study to evaluate the efficacy of topical pure emu oil for joint pain related to adjuvant aromatase inhibitor use in postmenopausal women with early breast cancer: JUST (Joints Under Study).* **Support Care Cancer**. 2017 Jul 9. doi: 10.1007/s00520-017-3810-9
- 73) Martín M, Chan A, Dirix L, O’Shaughnessy J, Hegg R, Manikhas A, Shtivelband M *A randomized adaptive phase II/III study of buparlisib, a pan-class I PI3K inhibitor, combined with paclitaxel for the treatment of HER2-advanced breast cancer (BELLE-4).* **Ann Oncol**. 2017;28:313-320
- 74) Chan A. *Trastuzumab biosimilar in early breast cancer setting: will there be direct patient benefits?* **Chin Clin Oncol** 2017;6(5):55. doi: 10.21037/cco.2017.10.03
- 75) Martin M, Holmes FA, Ejlersen B, Delaloge S, Moy B, Iwata H, von Minckwitz G, Chia SKL, Mansi J, Barrios CH, Gnant M, Tomašević Z, Denduluri N, Šeparović R, Gokmen E, Bashford A, Ruiz Borrego M, Kim SB, Jakobsen EH, Ciceniene A, Inoue K, Overkamp F, Heijns JB, Armstrong AC, Link JS, Joy AA, Bryce R, Wong A, Moran S, Yao B, Xu F, Auerbach A, Buyse M, Chan A

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. **Lancet Oncology 2017; 18(12):1688-1700**

- 76) Gianni L, Mansutti M, Anton A, Calvo L, Bisagni G, Bermejo B, Semiglazov V, Thill M, Chacon J, Chan A, Morales S, Alvarez I, Plazaola A, Zambetti M, Redfern A, Ditrich C, Dent R, Magazzù D, De Fato R, Valagussa P, Tusquets I Comparing Neoadjuvant Nab-paclitaxel vs Paclitaxel Both Followed by Anthracycline Regimens in Women With *ERBB2/HER2*-Negative Breast Cancer—the Evaluating Treatment With Neoadjuvant Abraxane (ETNA) Trial A Randomized Phase 3 Clinical Trial **JAMA Oncol. 2018**:Jan 18
- 77) Jeffrey L. Vacirca, Arlene Chan, Klara Mezei, Clarence S. Adoo, Zsuzsanna Papai, Kimberly McGregor, Meena Okera, Zsolt Horvath, Laszlo Landherr, Jerzy Hanslik, Steven J. Hager, Emad N. Ibrahim, Makharadze Rostom, Gajanan Bhat, Mi Rim Choi, Guru Reddy, Karen L. Tedesco, Richy Agajanian, Istvan Lang, DSc, Lee S. Schwartzberg An Open-Label, Dose-Ranging Study of Rolontis, a Novel Long-Acting Myeloid Growth 1 Factor, in Breast Cancer **Cancer Medicine 2018** doi: 10.1002/cam4.1388
- 78) Naomi L Brook, Emily S Brook, Arun Dharmarajan, Crispin Dass, Arlene Chan, Breast cancer bone metastases: pathogenesis and therapeutic targets **International J Biochemistry and Cell Biology 2018**
- 79) Arlene Chan, Astrid Bauwens, Sally Pontre, Sally Jackson, Frances McGlone, Tracie Ernenwein, Jun Chih, Christopher Reid Efficacy of scalp cooling in reducing alopecia in early breast cancer patients receiving contemporary chemotherapy regimens **The Breast 2018** (41)127-132
- 80) Matissek K, Onozato L, Sun S, Zheng Z, Schultz A, Lee J, Patel K, Jerevall P, Saladi S, Macleay A, Tavallai M, Badovinac-Crnjevic T, Barrios C, Beşe N, Chan A, Chavarri-Guerra Y, Debiasi M, Demirdögen E, Egeli Ü, Gökgöz S, Gomez H, Liedke P, Tasdelen I, Tolunay S, Werutsky G, St Louis J, Horick N, Finkelstein D, Le L, Bardia A, Goss P, Sgroi DC, Iafrate AJ, Ellisen L Expressed Gene Fusions as Frequent Drivers of Poor Outcomes in Hormone Receptor-Positive Breast Cancer. **Cancer Discov 2018**;8:336-353
- 81) Hiroji Iwata, Norikazu Masuda, Sung-Bae Kim, Kenichi Inoue, Yoshiaki Rai, Takashi Fujita, Zhen-Zhou Shen, Joanne Chiu, Shoichiro Ohtani, Masato Takahashi, Naohito Yamamoto, Toshiko Miyaki, Qiang Sun, Yen-Shen Lu, Binghe Xu, Yoon Sim Yap, Anita Bustam, Bin Yao, Bo Zhang, Richard Bryce, Arlene Chan Neratinib in the Extended Adjuvant Treatment of Early-Stage HER2-Positive Breast Cancer after Trastuzumab-Based Therapy: Efficacy and Safety Findings in Patients from Asia from the Randomized Phase III ExteNET Trial **Future Oncology 2018 (submitted)**
- 82) Suzette Delaloge, David Cella, Yining Ye, Marc Buyse, Arlene Chan, Carlos H. Barrios, Franki A. Holmes, Janine Mansi, Hiroji Iwata, Bent Ejlersen, Beverly Moy, Gunter von Minckwitz, Stephen K.L. Chia, Michael Gnant, Snezhana Smichkoska, Audrone Ciceniene, Isil Somali, Noelia Martinez,1 Sladjana Filipović, Noa Efrat Ben-Baruch, Anil A. Joy, Sven T. Langkjer, Francis Senecal, Richard H. de Boer, Susan Moran, Bin Yao, Richard Bryce, Alan Auerbach, Lesley Fallowfield, Miguel Martin Effects of Neratinib on Health-Related Quality-of-Life in Women with HER2-Positive Early-Stage Breast Cancer: Longitudinal Analyses from the Randomized Phase III ExteNET Trial **Annals of Oncology 2019** (in press)
- 83) Stephen K. L. Chia, Miguel Martin, Frankie A. Holmes, Bent Ejlersen, Suzette Delaloge, Beverly Moy, Hiroji Iwata, Gunter von Minckwitz, Janine Mansi, Carlos H. Barrios, Michael Gnant, Zorica Tomašević, Neelima Denduluri, Robert Šeparović, Sung-Bae Kim, Erik Hugger Jakobsen, Vernon Harvey, Nicholas Robert, John Smith, Graydon Harker, Bo Zhang, Lisa D. Eli, Yining Ye¹ Alshad S. Lalani, Marc

Buyse² and Arlene Chan PIK3CA Alterations and Benefit to Neratinib: Analysis from the ExteNET Trial **Breast Cancer Research 2019** (in press)

INVITED ORAL PRESENTATIONS

1998

Medical oncology towards year 2000	College of Medical Administrators Seminar, Perth
Advances in breast and prostate cancer	Perth Community Medical Group Seminar, Perth
Cancer information services training program	National Breast Cancer Center, Perth
Recurrent breast cancer: Cancer Update Breast forum	Cancer Foundation, Perth
Chemotherapy in palliative care	Palliative Care Study Day, Perth
Breast cancer genetics	Breast Screen WA Annual Meeting, Perth
Chemotherapy: role in palliative care	WA Hospice Palliative Care Association, Perth

1999

Chemotherapy: curative and palliative	Rotary Palliative Care Education Centre, Perth
Chemotherapy for breast cancer - what are the toxicities?	South Perth Clinical Society
Navelbine in breast cancer	Plenary lecture 1 st Navelbine Regional Meeting, Singapore
Recent advances in breast cancer	Oncology Nursing and Pharmacy Interest Group Annual Seminar, Perth
Living well with breast cancer recurrence	Cancer Foundation Breast Cancer Education Program, Perth
Selective oestrogen receptor modulators in breast cancer	Western Australia Clinical Oncology Group Breast Cancer Advisory committee Educational Session, Perth
Breast cancer genetics	Shakut Kahnum Hospital, Lahore, Pakistan
High risk breast cancer	Agar Kahn Hospital, Islamabad, Pakistan

2000

Recent advances in oncology in year 2000	Royal Australasian College of Physicians State of the Art Lecture, Perth
Breast cancer: role of genetics	WA Society of Plastic Surgeons Seminar, Perth
Aromatase inhibitors and their place in the treatment of breast cancer	Oncology Nursing and Pharmacy Interest Group Annual Seminar, Perth
Breast cancer workshop: Disease progression	Cancer Foundation of WA, Perth

2001

Management of hereditary breast cancer	WA Breast Screen Annual Meeting, Perth
Role of navelbine in breast cancer	Plenary lecture 3rd Navelbine Regional Meeting, Taipei Taiwan
Breast cancer: the latest in chemotherapy	Royal Australian and New Zealand College of Radiology Continuing Medical Education Seminar, Perth
Breast cancer update	Society of Hospital Pharmacists of Australia, Perth
Breast cancer: recent advances in clinical management	Royal Australasian College of Physicians Lecture Series
Breast cancer survival in WA	Western Australia Clinical Oncology Group, Cancer Council WA

2002

Update on clinical research in breast cancer	Western Australia Clinical Oncology Group, Cancer Council WA
Herceptin: clinical role in breast cancer	Frontiers in Medicine Lecture, Royal Perth Hospital
Establishment of a breast cancer risk assessment clinic	Western Australia Human Genetic Research Forum
Adjuvant chemotherapy in breast cancer	Breast Cancer Study Day, Royal Perth Hospital
2 nd state of the art conference in targeted cancer treatment	Montreaux, Switzerland
Role of adjuvant chemotherapy for early breast cancer	Royal College of Plastic Surgeon: Advanced Trainee Seminar, Perth
Workshop in management of breast cancer	Advanced Trainees Workshop, Perth
Update of breast cancer	Royal Australasian College of Physicians: Seminar, Perth

2003

Capecitabine in combination regimens for breast cancer	Plenary lecture Malaysian Society of Hematology & Malaysian Society of Oncology, Kuala Lumpur, Malaysia
Herceptin [®] : clinical role in breast cancer	Plenary lecture Malaysian Society of Hematology & Malaysian Society of Oncology, Kuala Lumpur, Malaysia
HER-family of receptors: prognostic markers and targets for therapy	Breast Cancer Diagnosis and Management Update; Breast Screen Western Australia (BSWA), Perth
Role of bisphosphonate therapy in breast cancer	Western Australian Clinical Oncology Group Education Meeting, Cancer Council WA
Tamoxifen and aromatase inhibitors: what are their roles in breast cancer?	Breast Screen WA General Practitioner Clinical Series, Perth
Breast cancer: interactive case discussions	Royal Australasian College of Physicians Lecture series, Perth
Clinical management of the high-risk woman Skin and Breast Cancer Update	General Practitioner Educational Seminar, Perth
How to evaluate cancer treatments and the limitations of this process with alternative therapies	Western Australia Clinical Oncology Group Breast Cancer Education Meeting, Cancer Council WA

2004

What you need to know about familial breast cancer	Breast Screen Western Australia (BSWA) Rural GP Conference
Breast cancer: early, advanced and genetic case discussions	Royal Australasian College of Physicians Lecture series

2005

Multidisciplinary meeting: controversies in breast cancer management	Plenary lecture Australian & New Zealand Breast Cancer Group, Sydney
Optimal surveillance and how good is it?	Plenary lecture Royal Australasian College of Surgeons Annual General Meeting, Perth
Aromatase inhibitors in early breast cancer	Plenary lecture Royal Australasian College of Surgeons Annual General Meeting, Perth
Long-term complications of chemotherapy	3 rd Multidisciplinary Breast Cancer Conference Breast Screen Western Australia (BSWA)

2006

X-panding options with first-line Xeloda combinations	Milestones in Management, Confidence in Care: An International Breast Cancer Expert Forum, Vienna, Austria
Role of docetaxel in adjuvant treatment of early breast cancer	Plenary lecture Korean Breast Cancer Society, Seoul, Korea
Optimal “chemo targeted” therapy for advanced breast cancer	Plenary lecture Australia and New Zealand Breast Cancer Trials Group, Annual Meeting, Cairns
Aromatase inhibitors & herceptin: current status in breast cancer	Oncology Nurses and Pharmacist Interest Group, Annual Meeting, Perth
Breast cancer overview	Royal College of Australasian Physician Advanced trainee Lecture, Perth
Lapatinib: overview and role in metastatic breast cancer	Korean Cancer Society, Seoul, Korea
Asia-Pacific Oncology Summit of breast cancer experts	Multidisciplinary meeting, Singapore

2007

Trastuzumab: review of adjuvant trials in early breast cancer	Plenary lecture Royal Australasian College of Surgeon Annual Meeting Christchurch New Zealand
Locally advanced breast cancer: need for a coordinated, multidisciplinary approach	Plenary lecture Royal Australasian College of Surgeon Annual Meeting Christchurch, New Zealand
Phase III trial comparing AC-T with AC-TH and with TCH in the adjuvant treatment of HER2 positive early breast cancer patients	Plenary lecture Asia Pacific Oncology Summit Chengdu, China
Breast cancer overview:	Royal College of Australasian Physician Advanced Trainee, Perth
EGF100151: Phase III randomised trial of lapatinib and Xeloda vs. Xeloda in metastatic breast cancer	Multidisciplinary Educational Meeting, Sydney
Current landscape and future directions of breast cancer chemotherapy	Plenary lecture 9 th National Breast Cancer Conference Beijing, China
Overview of adjuvant docetaxel trials	Plenary lecture 9 th National Breast Cancer Conference Beijing, China
Translating BCIRG trial findings into everyday clinical practice	Satellite Symposium. ECCO Barcelona, Spain
Use of herceptin in adjuvant breast cancer	Plenary lecture Global Breast Cancer Conference Seoul, Korea

2008

Navelbine & Herceptin – important role in Her2 neu positive breast cancer	Plenary lecture Breast Cancer Society Annual Meeting Tokyo, Japan
Evidence in first-line treatment for high-risk patients: HER2-positive metastatic disease	International Breast Cancer Experts Forum, Lisbon, Portugal
Treatment beyond progression Thought Leader Forum,	Thought Leader Forum, Berlin, Germany
Biologic therapy in breast cancer: How far have we come?	Plenary lecture Royal Australasian College of Surgeons Hong Kong

Adjuvant chemotherapy delivery: Is it all the same?	Plenary lecture Royal Australasian College of Surgeons Hong Kong
Use of Lapatinib for Her2 positive metastatic breast cancer	Breast cancer workshop Singapore

Multidisciplinary management of early breast cancer	General Practitioner Seminar Perth
Optimising the 3 'D's in breast cancer management: docetaxel, dose and duration	Plenary lecture 15 th International Conference on Cancer Nursing (ICCN) Singapore
Biology and treatment of Erb B2-positive breast cancer	Taiwan Breast Group Taipei, Taiwan
The Role of Tyrosine Kinase Inhibitor in the Treatment of Breast Cancer	Taiwan Breast Group Taipei, Taiwan

2009

Treatment Challenges in Node-Negative Early-Stage Breast Cancer Workshop	Plenary lecture International Breast Cancer Conference Paris, France
Controversial cases in breast cancer management Hematology and Oncological Targeted Treatment	HOTT symposium Melbourne
Real World Impact: Lapatinib plus capecitabine beyond the 151-trial	Plenary lecture Taiwan Joint Cancer Conference Taipei, Taiwan
Optimising treatments for ErbB2 driven breast cancer	Plenary lecture Global Breast Cancer Conference 7 th Biennial meeting of the Asian Breast Cancer Society Seoul, Korea
W3004 Clinical trial recruitment for delayed adjuvant neratinib	Multidisciplinary Educational Meeting, Hong Kong
Update on new advances in breast cancer management	Astra Zeneca Oncology Educational Symposium, Melbourne

2010

Triple negative breast cancer: biology and treatment options	Plenary lecture 4 th International Breast Cancer Conference, Paris, France
Management of HER2/neu negative breast cancer Workshop	Plenary lecture 4 th International Breast Cancer Conference, Paris, France
Biomarker evaluation in HER2/neu positive metastatic breast cancer	Shersig investigator meeting London, UK
Defining the benefits of anti-angiogenic therapy in specific settings & combinations. Art of Oncology	Plenary lecture Malaysian Oncology Society Kuala Lumpur, Malaysia
Choosing the optimal adjuvant chemotherapy regimen, dose and schedule Art of Oncology	Plenary lecture Malaysian Oncology Society Kuala Lumpur, Malaysia
Current & emerging treatment strategies in triple negative cancer Art of Oncology	Plenary lecture Malaysian Oncology Society Kuala Lumpur, Malaysia
Should all patients with HER2 negative mBC receive Avastin?	Thought Leader Forum Barcelona, Spain
Late adverse effects of adjuvant systemic therapy	Royal College of Surgeon Perth
HER2 Positive Breast Cancer: Why Early Treatment is Essential?	Malaysian Oncology Society Kuala Lumpur, Malaysia
Current recommendations in the use of aromatase inhibitors	Breast Physicians Forum Breast Screen Perth

Good Clinical Practice Training session for co-investigators	Mount Breast Group Perth,
Current recommendations in the use of aromatase inhibitor	General Practitioner Education Seminar, Perth
Overview of breast cancer	FRACP Part 1 Registrar Seminar August
Targets in Metastatic Breast Cancer	Medical Oncology Advance Trainees seminar Perth
Breast cancer overview Final year medical students lecture	Notre Dame University Perth,

2011

Challenging Cases in metastatic breast cancer (Chair) Workshop	5 th International Breast Cancer Conference, Paris France
Challenging Cases in early breast cancer Workshop	5 th International Breast Cancer Conference, Paris France
Management of HER2/neu positive and endocrine positive metastatic breast cancer	Medical Oncology group Singapore
Revisiting the Treatment Paradigm of ErbB2+ Metastatic Breast Cancer	Plenary lecture Malaysian Oncology Society Kuala Lumpur, Malaysia
Visiting Professor for Chinese International Medical Tribune, International CME Exchange Division to Shijiazhuang Cancer centre in Henan Province and Hongqiao Oncology Meeting	Plenary lecture CMA (Chinese International Medical Tribune) International CME Exchange Division Shanghai, China
Personalised Care in Breast Cancer: Controversies and Challenging Cases Perth	BCRC-WA: National Breast Cancer Workshop, Perth
Medical Oncology Advanced trainees: Multidisciplinary Management of Breast Cancer in 2011: A Clinical and Research approach to delivery of care Perth	BCRC-WA: National Breast Cancer Workshop, Perth
New drug therapies: toxicity profiles and challenges in delivery.	Clinical Oncology Society of Australia (COSA), Perth
The Estrogen Receptor Pathway: Resistance to Endocrine Therapy and New Therapeutic Approaches	Plenary lecture Asia Pacific Cancer Conference Kuala Lumpur, Malaysia

2012

Treatment and Prevention Strategies With Aromatase Inhibitors Plenary	International Breast Cancer Conference Nice France
New drugs in Breast cancer	Western Australia Clinical Oncology Group Perth
Ongoing evolution of anti-HER2 treatment in early breast cancer	Hematology and Oncology Targeted treat February 2012
Improving Protocols for Treatment of Women with Locally Advanced Breast Cancer	Asia Pacific Oncology Conference Taipei, Taiwan
Changing Landscape in Breast Cancer – Management issues in the East & West	Multidisciplinary meeting, Perth

2013

New Treatments and pathways	WACOG and Breast Tumour Collaborative Registrar and Fellow training day
Metastatic breast cancer – navigating through the landscape of treatment options	Australia and New Zealand Breast Cancer Trials Group, Annual Meeting, Brisbane

2014

Social and economic factors affecting delivery of cancer care in India	Plenary lecture Asian Oncology Summit April Kuala Lumpur, Malaysia
CNS disease in breast cancer: an unmet clinical need	Plenary lecture Asian Oncology Summit Kuala Lumpur, Malaysia
Non-anthracycline adjuvant regimens in operable breast cancer	Plenary lecture 3rd International Breast Cancer Symposium, Jeju Island Korea
Treatment opinion of HER2 positive breast cancer	Plenary lecture China 2 nd Conference of Individualised Management of breast cancer, Beijing, China
Commission into cancer care delivery in Russia, India and China	Annual Meeting of Medical Oncology Group of Australia
Post-ASCO Breast cancer update	WACE: Multidisciplinary meeting, June Perth
Best of ASCO 2014: Breast cancer	Annual Meeting of Medical Oncology Group of Australia Sydney,
Front line chemotherapy treatment choice: after antra-taxans in advanced breast cancer	Pierre Fabre Meeting: Metastatic breast cancer Beijing China
“Breaking bad news”	Advanced Trainee Seminar Perth
Metastatic breast cancer: Clinical trials	Breast Cancer Research Centre-WA GP Forum Perth Australia
Metastatic breast cancer: New drug therapy	Breast Cancer Research Centre-WA GP Forum Perth
Emerging breast cancer management challenges for the oncologist	Breast Screen WA 7 th Mutlidisciplinary Breast Cancer Conference Perth
Optimising Adjuvant Chemotherapy Dose Delivery	Contemporary Research Directions in Breast Cancer WACOG Perth

2015

What has been “learned” in 2014 for metastatic breast cancer ?	BCRC-WA: National Breast Cancer PYNKS - advanced breast cancer patient meeting Perth
Post-SABCS Breast cancer update	WACE: Multidisciplinary meeting, February Perth
Breast cancer in 2015: The global impact of advances in research	Plenary lecture Asian Oncology Summit April Kuala Lumpur, Malaysia
Neratinib after adjuvant chemotherapy and trastuzumab in HER2-positive early breast cancer: Primary analysis at 2 years of a phase 3, randomized, placebo-controlled trial (ExteNET)	Plenary lecture June American Society of Clinical Oncology Chicago, USA
WACOG meeting Post-ASCO Breast session	WACOG Meeting June 2015, WA
Best of ASCO Breast	Best of ASCO Singapore July
Limiting infection risk in patients receiving chemotherapy – the role of GCSF	Cancer Nurses Society of Australia WA June
Invasive disease-free survival benefit following neratinib as extended adjuvant therapy in centrally-confirmed HER2+ early-stage breast cancer: The ExteNET phase III randomized placebo-controlled trial	ASCO Breast Oral presentation San Francisco, USA
Metastatic breast cancer: Defining the impact & clinical issues, Treatment approach and treatment options	WACOG Metastatic breast cancer meeting, Perth

ExteNET Study: Neratinib after adjuvant chemotherapy and trastuzumab in HER2-positive early breast cancer	OOTR Translational Oncology Session at The 18th Annual Meeting of Chinese Society of Clinical Oncology (CSCO) September Xiamen, China
Invasive disease-free survival benefit following neratinib as extended adjuvant therapy in centrally-confirmed HER2+ early-stage breast cancer: The ExteNET phase III randomized placebo-controlled trial	American Society of Clinical Oncology, Breast Cancer Symposium San Francisco, USA
Debate: That all early stage HER2-positive patients should receive adjuvant anti-HER therapy? - NO	Plenary lecture World Congress on Controversies in Breast Cancer Melbourne, Australia 2015
Current endocrine strategies: Advantages and practical limitations	Plenary lecture World Congress on Controversies in Breast Cancer Melbourne, Australia 2015
Applying clinical guidelines in hormone receptor positive and HER2 negative disease: Breakout Session	Oncology Leaders Summit Helsinki, Finland
Maintaining the Ship—A Discussion of Adverse Events: Managing adverse events associated with current and emerging therapies for advanced breast cancer	Oncology Leaders Summit Helsinki, Finland
A Two-Pronged approach: Chemotherapy Versus Endocrine Therapies and Combination Targeted Therapies for HR+, HER2– Advanced Breast Cancer	Oncology Leaders Summit Helsinki, Finland
Neratinib after trastuzumab-based adjuvant therapy in early-stage HER2+ breast cancer: 3-year analysis from a phase 3 randomized, placebo-controlled, double-blind trial (ExteNET)	Plenary lecture San Antonio Breast Cancer Symposium, San Antonio, USA
Improving long term disease outcomes in Her2+ early breast cancer	prIME Oncology's Scientific Exchange program San Antonio Breast Cancer Symposium, San Antonio, USA

2016

Individualizing treatment for patients with HER2-positive mBC	2016 International Kaohsiung Symposium on Cancer of Excellent Research Kaohsiung City Taiwan
Overcoming endocrine resistant luminal breast cancer	Inaugural NSW Translational Breast Cancer Research Symposium, Sydney
Fighting breast cancer: can science and the body work together?	Rural Health West Annual Meeting, Perth
Mapping the breast cancer landscape in Asia	Asia Pacific Oncology Summit Seoul South Korea
Breast cancer update 2016	Breast Physician meetin Perth
The Latest Developments in Breast Chemotherapy	Genesis Cancer Care “Breaking New Ground” meeting Perth
Debate - That adjuvant Neratanib should be offered as a standard of care for HER2 positive patients	2nd World Congress on Controversies in Breast Cancer – CoBrCa Barcelona, Spain
What to do when Pertuzumab and TD-M1 have failed	2nd World Congress on Controversies in Breast Cancer – CoBrCa Barcelona, Spain

Breast cancer in 2016 - what is clinically relevant for family physicians	Rural West Annual Conference Perth
Breast cancer in Asian and Caucasian patients – tumour biology and treatment factors	Ramsay Sime Medical Conference Kuala Lumpur, Malaysia
How can we improve on current targeted therapies for HER2-positive breast cancer?	Tackling Hard to Treat Breast Cancer Subtypes: New Opportunities in Triple-Negative and HER2-Positive Disease: prIME Oncology Satellite Symposium San Antonio Breast Cancer Symposium 2016 San Antonio, USA

2017

Metastatic breast cancer	BCRC-WA Annual lecture on metastatic breast cancer (Public lecture) Perth WA
WACOG meeting Post-SABCS Breast session	WACOG Meeting, WA
Pursuing excellence - making a meaningful difference in women's lives	2017 Australian Women's Leadership Symposium Keynote lecture Perth
Breast cancer: Making a difference	Rotary WA 47th Ladies Seminar, Perth
Principles of management of resistant disease – medical oncology	11th Scientific Meeting of the Australasian Society for Breast Disease, Gold Coast
Principles of management of resistant disease – medical oncology	11th Scientific Meeting of the Australasian Society for Breast Disease, Gold Coast
Update on current neoadjuvant therapy trials	11th Scientific Meeting of the Australasian Society for Breast Disease, Gold Coast
Advances in treatment of HER2 positive breast cancer	11th Scientific Meeting of the Australasian Society for Breast Disease, Gold Coast
Neratinib should be offered as a standard of care in adjuvant therapy of HER2+ breast cancer - YES	3rd World Congress on Controversies in Breast Cancer (CoBrCa) Tokyo Japan
Liberal use of genetic testing should be encouraged – YES	3rd World Congress on Controversies in Breast Cancer (CoBrCa) Tokyo Japan
Life after early breast cancer: - dealing with the problems women face	Women's Health – A CPD meeting for general practitioners WA

2018

Implementation of best practice in treating advanced breast cancer	Eisai Symposium of Contemporary Oncology (ESCON) Taipei Taiwan
MBC Immunotherapy and chemotherapy	Eisai Symposium of Contemporary Oncology (ESCON) Taipei Taiwan
Ribociclib: Maximizing Rapid and Durable Outcomes in the Management of HR+ / HER2- advanced Breast Cancer	Action Hospital Grand Round, Delhi India
CDK 4/6 inhibitors: setting a new benchmark in management of HR+/HER2- advanced breast cancer	Indian Cooperative Oncology Network (ICON) Conference Kochi, India
WACE meeting Post-SABCS Breast session	WACOG Meeting, WA
Translational research: Collaboration between basic science and breast cancer clinical areas of need	Curtin University Post-Graduate Seminar

Workshop – Clinical trial conduct in breast cancer	Melbourne International Joint Breast cancer Congress, Melbourne Victoria
Metastatic breast cancer	BCRC-WA Annual lecture on metastatic breast cancer (Public lecture) Perth WA
That a bone targeted agent should be routine for post-menopausal HR+ve patients - YES	Melbourne International Joint Breast cancer Congress, Melbourne Victoria
Drug treatment for CNS metastasis	Melbourne International Joint Breast cancer Congress, Melbourne Victoria
WACOG meeting Post-ASCO Breast session	WACOG Meeting, WA